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2Sample Descriptions 
CAMH — Center for Addiction and Mental Health 
(Nazeri et al., 2013; Wheeler et al., 2014)  
Recruitment. Patients and controls were recruited at the Center for Addiction and Mental 
Health (CAMH) in Toronto, Canada, via referrals, study registries, and advertisements. All clinical 
assessments occurred at CAMH and MRI scans were performed at a nearby general hospital in 
Toronto. Community-dwelling outpatients with schizophrenia were individually matched based on 
age, sex, handedness, and highest parental years of education to healthy controls. Controls form 
part of the Cognitive Genomics Consortium wave 2 (COGENT2) dataset (Trampush et al., 2017).  
Inclusion/Exclusion Criteria. All participants were between 18 and 85 years of age. All 
participants received urine toxicology screens and anyone with current substance abuse or any 
history of substance dependence was excluded. Individuals with previous head trauma with loss 
of consciousness or neurological disorders were also excluded. For controls, a history of a primary 
psychotic disorder in first-degree relatives was also an exclusion criterion. 
Clinical/Neuropsychological Assessment. All participants were interviewed by a psychiatrist 
and were administered the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I; First 
et al., 1995b) to determine diagnosis and duration of illness. The Positive and Negative Syndrome 
Scale (PANSS; Kay et al., 1987) and Clinical Global Impression Scale (CGI-S; Guy, 2000) were 
administered to further characterize illness symptoms. Burden of comorbid physical illness was 
measured by the Cumulative Illness Rating Scale for Geriatrics (Miller et al., 1992). Medication 
histories were initially recorded based on self-reports, and then verified either by the patient’s 
treating psychiatrist or chart review. All participants underwent a battery of cognitive tests 
administered over approximately 1.5 hours. Premorbid IQ was measured using the Wechsler Test 
for Adult Reading (WTAR; Wechsler, 2001). The cognitive battery consisted of the subtests Digit 
Symbol Coding, Semantic Verbal Fluency, Digit Span, List Learning, Story Memory, and Figure 
Recall from the Repeated Battery for the Assessment of Neuropsychological Status (RBANS; 
Randolph et al., 1998), as well as the Trail Making Test-Part A and B (Reitan, 1958) and 
Controlled Oral Word Association Test (COWAT) of Phonemic Verbal Fluency (letters: F, A, S) 
(Reitan, 1985) to measure processing speed, University of Maryland Letter-Number Span (Gold 
et al., 1997) to measure verbal working memory, Stroop test to measure executive function 
(Stroop, 1935), Grooved Pegboard (Lafayette Instrument Company -- Trites, 1989) and Finger 
Tapping (Ruff and Parker, 1993) to assess psychomotor speed.  
MRI Acquisition. T1-weighted structural scans (Echo Time [TE] = 5.3 ms; Inversion Time [TI] 
= 300 ms; Repetition Time [TR] = 12.3 ms; Flip angle = 20°; Field of View [FOV] = 20 cm; Spatial 
resolution = 0.78 x 0.78 x 1.5 mm; matrix = 256 x 256 mm; Slice acquisition direction = axial, AC-
PC oblique) and Diffusion Tensor Imaging (TE = 85.5 ms; TR = 15000 ms; Flip angle = 90°; FOV 
= 33 cm; Spatial resolution = 2.6 x 2.6 x 2.6 mm; matrix = 128 x 128 mm; Slice acquisition direction 
= axial, oblique; number of diffusion-encoding gradient directions = 23; number of b0 volumes = 
2; b-value = 1000 s/mm2) were acquired on a 1.5 Tesla General Electric (GE) Echospeed scanner 
using an 8-channel head coil. 
Genotyping. DNA obtained from whole blood was genotyped on the Illumina OmniExpress 
array. 
Ethics/Consent. The study was approved by the Research Ethics Board of CAMH and all 
participants provided informed written consent. 
Acknowledgements. Data acquisition was supported by the Canadian Institutes of Health 
Research, Ontario Mental Health Foundation, the Brain and Behavior Research Foundation 
(formerly NARSAD), the Centre for Addiction and Mental Health (CAMH), and the CAMH 
Foundation through the Kimel Family, Koerner New Scientist Award, and Paul E Garfinkel New 
3Investigator Catalyst Award. The investigators acknowledge the assistance of David J. Rotenberg 
and Dr. Daniel Felsky. 
CATIE — Clinical Antipsychotic Trials of Intervention Effectiveness 
(Keefe et al., 2006; Lieberman, 2007; McClay et al., 2011; Stroup et al., 2003; Sullivan et al., 
2008) 
Recruitment. Patients were recruited from 57 clinical settings across the United States for a 
multiphase randomized controlled trial of antipsychotic medications, including the second-
generation drugs, olanzapine, quetiapine, risperidone, and ziprasidone, compared with a 
midpotency first-generation drug, perphenazine. Patients were followed for up to 18 months. 
Patients who gave informed consent to participate in genetic studies are included in GENUS. 
Patients formed part of the Psychiatric Genomics Consortium Schizophrenia Working Group 
dataset (PGC Schizophrenia Working Group, 2014). 
Inclusion/Exclusion Criteria. Eligible patients were 18 to 65 years of age; had received a 
diagnosis of schizophrenia (not schizoaffective disorder), as determined on the basis of the SCID; 
and were able to take oral antipsychotic medication, as determined by the study doctor. Patients 
were excluded if they had received a diagnosis of schizoaffective disorder, mental retardation, or 
other cognitive disorders; had a history of serious adverse reactions to the proposed treatments; 
had had only one schizophrenic episode; had a history of treatment resistance, defined by the 
persistence of severe symptoms despite adequate trials of one of the proposed treatments or 
prior treatment with clozapine; were pregnant or breastfeeding; or had a serious and unstable 
medical condition. Patients with medical or psychiatric comorbidities those who require 
concomitant other medications are included. The patients who enroll in this study have chronic or 
recurrent schizophrenia. First episode patients and wholly treatment-refractory patients are 
excluded. First episode patients are excluded because of their high rates of response to 
antipsychotic medications at relatively low doses. Treatment-refractory patients are excluded 
because their severe illness may preclude detection of differential effectiveness that would be 
apparent in treatment-responsive patients. 
Clinical/Neuropsychological Assessment. Schizophrenia patients were diagnosed using the 
SCID (First et al., 1994). Clinical rating scales include the PANSS (Kay et al., 1987), Calgary 
Depression Scale for Schizophrenia (CDSS; Addington et al., 1992), and Clinical Global 
Impression Scale (CGI-S; Guy, 2000). Premorbid IQ was measured using the Reading subtest 
from the Wide Range Achievement Test, Third Edition (WRAT-3; Wilkinson, 1993). Processing 
speed was measured using the Wechsler Adult Intelligence Scale, Revised Version (WAIS-R) 
Digit Symbol subtest (Wechsler, 1981), Semantic Verbal Fluency (categories: animals, fruits, 
vegetables) (Benton and Hamsher, 1978), and COWAT Phonemic Verbal Fluency (letters: F, A, 
S) (Reitan, 1985); attention/vigilance was measured using the Continuous Performance Test-
Identical Pairs version (CPT-IP; Cornblatt et al., 1988); spatial and verbal working memory were 
assessed using the computerized Spatial Delayed Response Task (Lyons-Warren et al., 2004) 
and University of Maryland Letter-Number Span (Gold et al., 1997), respectively. Verbal learning 
and memory was assessed with the Hopkins Verbal Learning Test (HVLT; Brandt, 1991). 
Executive function was assessed using the Wisconsin Card Sorting Test (WCST; Heaton et al., 
1993) and the Mazes subtest from the Wechsler Intelligence Scale for Children, Third Edition 
(WISC-III; Wechsler, 1991). Grooved Pegboard (Lafayette Instrument Company -- Trites, 1989) 
was used to measure psychomotor speed and the Facial Emotion Discrimination Test (Kerr and 
Neale, 1993) measured social cognition. 
MRI Acquisition. Not applicable. 
Genotyping. DNA obtained from whole blood was genotyped on the Affymetrix 500K array 
and Perlegen’s custom 164K chip. Genotype data are available from the NIMH Repository and 
Genomics Resource (http://www.nimhgenetics.org). 
4Ethics/Consent. All participants or their legal guardians gave written informed consent and the 
institutional review board at each site approved the study. 
Acknowledgements. The principal investigators were Jeffrey A. Lieberman, M.D., T. Scott 
Stroup, M.D., M.P.H., and Joseph P. McEvoy, M.D. The CATIE trial was funded by a grant from 
the National Institute of Mental Health (N01 MH900001) along with MH074027 (PI PF Sullivan). 
Genotyping was funded by Eli Lilly and Company. 
Conflicts of interest. Dr. Sullivan reports receiving research funding from Eli Lilly in connection 
with the CATIE project. Dr. Stroup reports having received research funding from Eli Lilly and 
consulting fees from Janssen Pharmaceutica, GlaxoSmithKline, and Bristol-Myers Squibb. Dr. 
Lieberman reports having received research funding from AstraZeneca Pharmaceuticals, Bristol-
Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica, and Pfizer and consulting and 
educational fees from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Forest 
Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Pfizer, and Solvay. 
CIDAR/VA — Boston CIDAR Study / Veterans Affairs Healthcare System 
(Clemm von Hohenberg et al., 2014; del Re et al., 2014; Kikinis et al., 2010; Kikinis et al., 2015; 
Pasternak et al., 2012; Quan et al., 2013; Seitz et al., 2016) 
Recruitment. Participants were recruited through the Boston CIDAR study (www.bostoncidar. 
org) and the Veterans Affairs Healthcare System. The participants included in the GENUS dataset 
consisted of clinical high-risk individuals with prodromal symptoms who also have a family history 
of schizophrenia (included in the FHR group), individuals within the first episode of schizophrenia, 
and individuals with chronic schizophrenia, as well as group-matched healthy control participants. 
Patients and FHR participants were recruited by referrals from clinicians or through local hospitals 
and clinics, and controls were recruited through newspaper and website advertisements. Patient 
and control participants of European ancestry formed part of the Psychiatric Genomics 
Consortium Schizophrenia Working Group dataset (PGC Schizophrenia Working Group, 2014). 
Inclusion/Exclusion Criteria. Exclusion criteria for controls included any current or past major 
DSM-IV-TR Axis I disorder, developmental disorders, psychiatric hospitalizations, prodromal 
symptoms, schizotypal or other Cluster A personality disorders, a first degree relative with 
psychosis, or current or past use of antipsychotics. Sleeping aids or anxiolytic agents for 
occasional use were acceptable, as well as other past psychotropic medication use if not within 
the prior 6 months. Exclusion criteria for all participants included sensory-motor handicaps, 
neurological disorders, medical illnesses that significantly impair neurocognitive function, 
diagnosis of intellectual disability (IQ<70), not fluent in English, DSM-IV substance abuse within 
the past month or dependence within the past 3 months, current suicidality, or history of 
electroconvulsive therapy for controls or electroconvulsive therapy within the past 5 years for 
patients. All first episode patients met DSM-IV-TR criteria for schizophrenia, schizoaffective 
disorder or schizophreniform disorder, and none had more than one year of continuous 
antipsychotic treatment. Chronic patients met DSM-IV-TR criteria for schizophrenia or 
schizoaffective disorder and had illness duration of at least five years. Inclusion criteria for clinical 
high-risk participants was predominantly presence of ‘late prodromal syndromes’ as classified by 
the Criteria of Prodromal States (Woods et al., 2001) based on the Scale of Prodromal Symptoms 
(Miller et al., 2003; Miller et al., 1999). Of the clinical high-risk participants, 14 participants fulfilled 
the GENUS definition of FHR. Controls were drawn from the same geographic bases with 
comparable age, gender, race and ethnicity, handedness, and parental socioeconomic status 
evaluated using the Hollingshead two-factor index (Hollingshead, 1975).  
Clinical/Neuropsychological Assessment. Trained and skilled interviewers and 
neuropsychological testers conducted all clinical and cognitive assessments. DSM-IV diagnoses 
were based on interviews with the Structured Clinical Interview for DSM-IV-TR (SCID), Research 
Version (First et al., 2002b) and information from patient medical records. The Scale for the 
Assessment of Negative Symptoms (SANS; Andreasen, 1983) and the Scale for the Assessment 
5of Positive Symptoms (SAPS; Andreasen, 1984) were used to measure symptom severity. The 
Global Assessment of Functioning (GAF; American Psychiatric Association, 2000) and CGI-S 
(Guy, 2000) were used to measure overall functioning. Participants were administered a large 
neurocognitive test battery including tests estimating premorbid IQ (the Reading subtest from the 
Wide Range Achievement Test-4 (WRAT-4; Wilkinson and Robertson, 2006a) and current IQ (the 
Vocabulary and Block Design subtests of the Wechsler Abbreviated Scale of Intelligence (WASI; 
Wechsler, 1999). The Brief Assessment of Cognition in Schizophrenia (BACS) Symbol Coding 
test (Keefe et al., 2008), the Trail Making Test-Part A (Reitan, 1958), and Semantic Verbal 
Fluency (MCCB Category Fluency; category: animals) (Benton and Hamsher, 1978; Kern et al., 
2008; Nuechterlein et al., 2008) were used for processing speed; the Continuous Performance 
Test-Identical Pairs version (Cornblatt et al., 1988) was used to measure attention/vigilance; the 
Wechsler Memory Scale, Third Edition (WMS-III) Spatial Span subtest (Wechsler, 1997b) and 
University of Maryland Letter-Number Span (Gold et al., 1997) were used for assessing working 
memory. The ‘vigilance’, ‘working memory’ and ‘working memory plus interference’ measures 
from the Seidman Auditory Continuous Performance Test battery (Auditory CPT; (Seidman et al., 
1998; Seidman et al., 2006). The Hopkins Verbal Learning Test-Revised (HVLT-R; Brandt and 
Benedict, 1997) and the WMS-III Logical Memory subtest (Wechsler, 1997b) assessed verbal 
learning and memory. The Brief Visuospatial Memory Test-Revised (BVMT-R; Benedict, 1997) 
assessed visual learning. Executive function was measured using the Mazes subtest of the 
Neuropsychological Assessment Battery (NAB; Stern and White, 2003) and the computerized 
WCST (Heaton, 2003; Heaton et al., 1993; Nestor et al., 1993). Finally, the Proverbs subtest from 
the Delis-Kaplan Executive Function System (D-KEFS; (Delis et al., 2001; Delis et al., 2004)) was 
administered to assess verbal ability, and Grooved Pegboard (Lafayette Instrument Company -- 
Trites, 1989) and Finger Tapping (Ruff and Parker, 1993) were administered to assess 
psychomotor speed. Social cognition was assessed using the Mayer–Salovey–Caruso Emotional 
Intelligence Test (MSCEIT; Mayer et al., 2003). 
MRI Acquisition. T1-weighted structural scans of schizophrenia and age-gender-handedness 
matched controls were acquired at Brigham and Women’s Hospital, Harvard University (TE = 3.0 
ms; TI = 600 ms; TR = 7.8 ms; Flip angle = 10°; FOV = 25.6 cm; Spatial resolution = 1.0 x 1.0 x 
1.0 mm; matrix = 256 x 256 mm; Slice acquisition direction = sagittal) and Diffusion Tensor 
Imaging (TE = 78 ms; TR = 17000 ms; Flip angle = 90°; FOV = 24 cm; Spatial resolution = 1.67 
x 1.67 x 1.7 mm; matrix = 144 x 144 mm; Slice acquisition direction = axial, AC-PC; number of 
diffusion-encoding gradient directions = 51; number of b0 volumes = 8; b-value = 900 s/mm2) 
were acquired on a 3 Tesla GE  Signa HDxt Echospeed scanner using an 8-channel head coil. 
T1-weighted structural scans of FHR participants and age-gender-handedness matched 
controls were acquired at Massachusetts General Hospital, Martinos Center, Harvard University, 
on a 3 Tesla Siemens Trio Tim scanner using a 32-channel head coil (TE = 3.48 ms; TI = 900 ms; 
TR = 2530 ms; Flip angle = 9°; FOV = 25.6 cm; Spatial resolution = 1.0 x 1.0 x 1.33 mm; matrix 
= 256 x 256 x 128 mm; Slice acquisition direction = sagittal) and Diffusion Tensor Imaging (TE = 
84 ms; TR = 9400 ms; Flip angle = 90°; FOV = 25.6 cm; Spatial resolution = 2.0 x 2.0 x 2.0 mm; 
matrix = 128 x 128 mm; Slice acquisition direction = axial; number of diffusion-encoding gradient 
directions = 60; number of b0 volumes = 10; b-value = 700 s/mm2). 
Genotyping. DNA was obtained from whole blood or saliva and genotyped on the Illumina 
OmniExpress array. 
Ethics/Consent. The study was approved by the local IRB committees at Harvard Medical 
School, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brigham and 
Women’s Hospital and the Veteran Affairs Boston Healthcare System (Brockton campus). All 
study participants, or legal guardians for those under 18 years of age, gave written informed 
consent and received payment for participation. 
Acknowledgements. Data acquisition was supported by the National Institute of Mental Health 
(NIMH) of the National Institutes of Health (NIH) under Award Numbers P50 MH080272 (RW 
6McCarley), U01MH081928 (LJ Seidman), R21MH106793 (Z Kikinis), and a NARSAD Young 
Investigator Award (Z Kikinis). Genotyping was funded by a Massachusetts General Hospital 
Executive Committee on Research Interim Support Fund award (TL Petryshen). The investigators 
thank all subjects for their participation in the study, the clinical and data management staff from 
the Boston CIDAR study and the Commonwealth Research Center (Dr. Matcheri Keshavan, Dr. 
Joanne Wojcik, Ann Cousins, Dr. Michelle Friedman-Yakoobian, Dr. Anthony J Giuliano, Andrea 
Gnong Granato, Lauren Gibson, Sarah Hornbach, Julia Schutt, Dr. Kristy Klein, Dr. Maria Hiraldo, 
Dr. Grace Francis, Corin Pilo, Rachael Serur, Grace Min, Alison Thomas, and Molly Franz), 
Tamara Tasoff, Dr. Beril Yaffe, and Danbee Kim for electrophysiology assistance (Harvard), and 
Kimberly Chambert (Broad Institute of MIT and Harvard), Patience Gallagher, Dr. Stephen 
Haddad, Brian Galloway, and Jenna Tarasoff (Massachusetts General Hospital) for genotyping 
assistance. 
COGS-UK — Cognition in Schizophrenia, Cardiff University, UK  
Recruitment. Patients were ascertained from psychiatric outpatient units, via voluntary mental 
health organizations and by public advert and entered the study following a telephone screening 
interview and confirmation of a clinical diagnosis of a non-affective psychosis by the treating 
clinical team. The sample consisted of white Caucasians, born in the UK and with British ancestry.  
Inclusion/Exclusion Criteria. Patients were screened to exclude substance-induced psychotic 
disorder or psychosis due to a general medical condition. All patients were diagnosed with 
schizophrenia, schizophreniform or schizoaffective diagnoses. 
Clinical/Neuropsychological Assessment. A semi-structured interview was administered to all 
patients by trained psychiatrists or psychologists. The comprehensive clinical phenotype battery 
included the Schedules for Clinical Assessment in Neuropsychiatry (SCAN; Wing et al., 1990)) 
sections on psychosis and affective symptoms, substance use, and family history as well as 
demographic details and a separate cognitive battery. Diagnosis was made according to DSM-IV 
criteria by experienced psychiatrists accessing the clinical interview data and case notes when 
appropriate. Clinical rating scales administered included SANS/SAPS (Andreasen, 1983, 1984), 
CDSS (Addington et al., 1992), and GAF (American Psychiatric Association, 1994). Premorbid IQ 
was estimated using the National Adult Reading Test (NART; (Nelson, 1982; Nelson and Willison, 
1991)). Cognitive testing was performed using the MATRICS Consensus Cognitive Battery 
(MCCB; (Kern et al., 2008; Nuechterlein et al., 2008)). The MCCB evaluates seven domains of 
cognitive function including: speed of processing using the BACS Symbol Coding subtest (Keefe 
et al., 2008), Trail Making Test—Part A (Reitan, 1958), and Semantic Verbal Fluency (MCCB 
Category Fluency; category: animals) (Benton and Hamsher, 1978; Kern et al., 2008; 
Nuechterlein et al., 2008); attention using the Continuous Performance Test—Identical Pairs 
(CPT-IP; Cornblatt et al., 1988); working memory using the WMS-III Spatial Span subtest 
(Wechsler, 1997b) and University of Maryland Letter-Number Span (Gold et al., 1997) (spatial 
and letter-number span); verbal learning using the HVLT-R (Brandt and Benedict, 1997); visual 
learning using the BVMT-R (Benedict, 1997); reasoning and problem solving using the NAB 
Mazes subtest (Stern and White, 2003); and social cognition using the MSCEIT (Mayer et al., 
2003). Finally, the D-KEFS Proverbs subtest (Delis et al., 2001; Delis et al., 2004) was 
administered to assess verbal ability. 
MRI Acquisition. Not applicable. 
Genotyping. DNA obtained from whole blood from a proportion of patients was genotyped on 
the Illumina Infinium OmniExpressExome-8 array.  
Ethics/Consent. The UK Multi-center Research Ethics Committee (MREC) approved the 
study, as did relevant local research and development committees. All participants provided valid 
informed consent for the study.   
Acknowledgements. The investigators wish to acknowledge Dr. Antonio F. Pardiñas and Amy 
Lynham for their assistance. 
7GAP — Genetics and Psychosis study 
(O'Connor et al., 2013; Reis Marques et al., 2014; Theleritis et al., 2014; Vassos et al., 2017) 
Recruitment. First episode psychosis patients were recruited as part of the National Institute 
of Health Research (NIHR) Biomedical Research Centre (BRC) Genetics and Psychosis study. 
Patients were approached if they appeared to meet DSM-IV criteria for schizophrenia or related 
disorder, or affective disorder with psychotic features and presented to one of 3 south London 
boroughs' geographical catchment area-based adult mental health services services of the South 
London and Maudsley NHS Foundation Trust (SLaM). During the same period a healthy control 
group was recruited from the local population living in the area and served by the SLaM Trust by 
means of internet and newspaper advertisements, and distribution of leaflets at train stations, 
shops and job centers. Particular attention was directed at attempting to obtain a control sample 
similar to the patient sample in age, gender, ethnicity, educational qualifications and employment 
status (Di Forti et al., 2009). 
Inclusion/Exclusion Criteria. Between August 2008 and July 2011, patients aged between 18–
65 years presenting for the first time to psychiatric services with a functional psychotic illness 
(ICD-10: F20-29, F30-34 excluding coding F1x.0 for acute intoxication; World Health 
Organization, 1992)). Inclusion criteria required that patients have 7 or more consecutive days of 
psychotic symptom(s) and were presenting to services for the first time with these symptoms. 
Patients were approached as soon as possible (up to 3 months after first contact). Exclusion 
criteria were: presence of an organic psychosis (i.e. known organic cause for psychosis), a 
moderate or severe developmental learning disability (as defined by ICD-10 F70-73), pregnancy, 
history of a medical or physiological cause of gonadal dysfunction (including hypothyroidism or 
other endocrine or metabolic disorder), vascular disorders, neurological disorders, antipsychotic 
treatment longer than 30 days (to minimize the effect of antipsychotics on BDNF levels), poor 
English fluency, and history of contact with health services for psychosis beyond the previous 6 
months. Participants completed all measures within 6 months of first presentation with services. 
At 12 months after initial assessments, some research measures were repeated via clinical notes 
or face-to-face interview when available. Information about employment, relationships, living 
status and medication, was collected through interview with the patient and searching clinical 
records. Diagnosis was made according to DSM-IV criteria using the Operational Criteria 
(OPCRIT; McGuffin et al., 1991) based on the clinical notes for the month after first contact with 
psychiatric services for psychosis. Raters were experienced researchers who were extensively 
trained and demonstrated adequate inter-rater reliability on clinical and neuropsychological 
assessment. All diagnoses were carried out by qualified psychiatrists and clinical researchers, 
subject to comprehensive training and inter-rater reliability testing.  
Clinical/Neuropsychological Assessment. Socio-demographic data (age, gender, self-
reported ethnicity, level of education attainment) were collected using the Medical Research 
Council Social Scale (Mallett et al., 2002). Medication histories were completed using information 
from patients and electronic clinical records. The GAF (American Psychiatric Association, 1994) 
was used to rate both severity of symptoms and disability. Two separate ratings on the GAF were 
assigned based on dimensions of psychiatric symptoms and psychological, social and 
occupational function. To rate specific psychotic symptoms, scored on a clinical interview, the 
PANSS was used (Kay et al., 1987). Neuropsychological assessments included the following 
measures: premorbid IQ from the WTAR (Wechsler, 2001) or NART (Nelson, 1982; Nelson and 
Willison, 1991; Russell et al., 2000)); spatial and verbal working memory using the WMS-III 
Spatial Span subtest (Wechsler, 1997b) and the Digit Span subtest from the Wechsler Adult 
Intelligence Scale, Third Edition (WAIS-III; Wechsler, 1997a)) and the Spatial Working Memory 
subtest from the Cambridge Neuropsychological Test Automated Battery (CANTAB; Cambridge 
Cognition, 2003a)); attention/processing speed using Trail Making Test—Part A (Reitan, 1958), 
WAIS-III Digit Symbol (Wechsler, 1997a), Semantic Verbal Fluency (categories: animals, body 
8parts, fruits) and Phonemic Verbal Fluency (letters F, A, S); verbal learning and memory was 
assessed using WMS-III Logical Memory (Wechsler, 1997b); visual memory using WMS-III Visual 
Reproduction; executive function was assessed using Trail Making Test—Part B (Reitan, 1958) 
and CANTAB Tower of London (Cambridge Cognition, 2003a). Additionally, the WAIS-III subtests 
Block Design, Matrix Reasoning, and Information, along with Digit Symbol and Digit Span were 
administered to allow for a calculation of total current IQ (Wechsler, 1997a). 
MRI Acquisition. T1-weighted structural scans (TE = 2.85 ms; TI = 650 ms; TR = 6.99 ms; Flip 
angle = 8°; FOV = 26 cm; Spatial resolution = 1.0 x 1.0 x 1.2 mm; matrix = 256 x 256 mm; Slice 
acquisition direction = sagittal) and Diffusion Tensor Imaging (TE = 104.8 ms; TR = 15000 ms; 
Flip angle = 90°; FOV = 30.7 cm; Spatial resolution = 2.4 x 2.4 x 2.4 mm; matrix = 128 x 128 mm; 
Slice acquisition direction = axial; number of diffusion-encoding gradient directions = 32; number 
of b0 volumes = 4; b-value = 1300 s/mm2) were acquired on a 3 Tesla GE Signa HDx scanner 
using an 8-channel head coil. 
Genotyping. DNA from a proportion of participants was extracted from blood or cheek swabs 
(80% and 20% of the participants, respectively) and genotyped on the Illumina HumanCore-24 
Exome BeadChip. 
Ethics/Consent. Ethical approval was obtained from the local research ethics committee. All 
study participants gave full informed consent. After hearing a complete description of the study 
and having the opportunity to ask questions, participants gave written informed consent.
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IMH-SIGNRP — Institute of Mental Health, Singapore Imaging Genetics and 
Neuropsychological Research in Psychosis 
(Ho et al., 2016; Kuswanto et al., 2015) 
Recruitment. Chinese ethnicity patients diagnosed with DSM-IV schizophrenia were recruited 
from the Institute of Mental Health, Singapore. Age- and gender-matched healthy controls were 
recruited from the staff population at the hospital, as well as from the community by 
advertisements. 
Inclusion/Exclusion Criteria. Participants with history of any significant neurological illnesses 
such as seizure disorder, head trauma, or cerebrovascular accident were excluded. No subject 
met DSM-IV criteria for alcohol or other substance abuse in the preceding 3 months. Patients 
were maintained on a stable dose of antipsychotic medication for at least two weeks prior to the 
recruitment and did not have their medications withdrawn for the purpose of the study. Healthy 
controls were deemed not to suffer from any Axis I psychiatric disorder and had no history of any 
major neurological, medical illnesses, substance abuse or psychotropic medication use.  
9Clinical/Neuropsychological Assessment. All diagnoses were made by a psychiatrist using 
information obtained from the existing medical records, clinical history, mental status examination, 
interviews with the patients and their significant family members, as well as the administration of 
SCID-I, Patient Version (SCID-I/P; First et al., 1994). Healthy controls were screened using the 
SCID-I, Non-Patient Version (SCID-I/NP; First et al., 2002a). Psychotic symptom levels were 
assessed using the PANSS (Kay et al., 1987). Premorbid IQ was assessed using the Reading 
subscale of the WRAT-3 (Wilkinson, 1993). The Symbol Coding, Category Instances (category: 
supermarket items), COWAT Phonemic Verbal Fluency (Reitan, 1985) (letters: F and S), Digit 
Sequencing, List Learning, and Tower of London (Shallice, 1982) subtests from the BACS (Keefe 
et al., 2004) were administered to assess attention/processing speed, verbal working memory, 
verbal learning and memory, and executive function, respectively.  
MRI Acquisition. T1-weighted structural scans (TE = 3.3 ms; TI = 860 ms; TR = 7.2 ms; Flip 
angle = 8°; FOV = 23 cm; Spatial resolution = 0.9 x 0.9 x 0.9 mm; matrix = 256 x 256 mm; Slice 
acquisition direction = axial) and Diffusion Tensor Imaging (TE = 56 ms; TR = 3725 ms; Flip angle 
= 90°; FOV = 23 cm; Spatial resolution = 0.9 x 0.9 x 3.9 mm; matrix = 112 x 109 mm; Slice 
acquisition direction = axial, AC-PC; number of diffusion-encoding gradient directions = 15; 
number of b0 volumes = 1; b-value = 800 s/mm2) were acquired on a 3 Tesla Philips Intera 
Achieva scanner using a SENSE 8-channel head coil. 
Genotyping. DNA from a proportion of participants was obtained from whole blood and 
genotyped on one of three arrays: Illumina Human OmniZhongHua-8, Illumina Human1M-Duo, 
or Affymetrix 6.0. 
Ethics/Consent. This study was approved by the Institutional Review Board of the Institute of 
Mental Health, Singapore, as well as the National Neuroscience Institute, Singapore. Participants 
gave written informed consent to participate in the study after a detailed explanation of the study 
procedure. 
Acknowledgements. Data acquisition was supported by the National Research Foundation 
Singapore under the National Medical Research Council Translational and Clinical Research 
Flagship Programme (grant no. NMRC/TCR/003/2008) for The Singapore Translational and 
Clinical Research in Psychosis, as well as research grants from the National Medical Research 
Council under the Centre Grant Programme (Institute of Mental Health, Singapore) 
(NMRC/CG/004/2013), the National Healthcare Group, Singapore (SIG/05004; SIG/05028), and 
the Singapore Bioimaging Consortium (RP C-009/2006). The investigators wish to acknowledge 
the contribution of Mingyuan Wang. 
IMH-STCRP — Institute of Mental Health, Singapore Translational and Clinical Research in 
Psychosis 
(Lam et al., 2014) 
Recruitment. Patients and healthy controls were recruited as part of the Singapore 
Translational and Clinical Research in Psychosis. Patients were recruited from rehabilitation 
centers, community care centers across the country, out-patient clinics and in-patient wards, 
under purview of the Institute of Mental Health, Singapore. Data collection was completed in 
approximately 3 years. Controls were from the Singapore Prospective Study Program and were 
randomly sampled from the Singapore population. Participants form part of the Psychiatric 
Genomics Consortium Schizophrenia Working Group dataset (PGC Schizophrenia Working 
Group, 2014). 
Inclusion/Exclusion Criteria. Inclusion criteria were: Chinese ethnicity, to ensure a genetically 
homogeneous sample; and completion of a minimum of 6 years of primary school education. 
Additional exclusion criteria precluded all participants with significant history of substance abuse, 
clinically significant neurological disease or injury, color blindness, and healthy participants with 
first-degree relatives suffering from schizophrenia or other psychotic disorders.  
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Clinical/Neuropsychological Assessment. Clinical and neuropsychological evaluations were 
carried out by psychometricians. Schizophrenia patients fulfilled Diagnostic and Statistical Manual 
of Mental Disorders, fourth edition (DSM-IV) diagnostic criteria for schizophrenia based on the 
SCID-I (First et al., 2002b). Psychotic symptoms were assessed using the PANSS (Kay et al., 
1987). Neuropsychological tests administered included the Matrix Reasoning subtest of the 
Wechsler Abbreviated Scale of Intelligence (WASI; Wechsler, 1999) as a measure of current IQ, 
Continuous Performance Tests-Identical Pairs (CPT-IP; Cornblatt et al., 1988) to measure 
attention/vigilance, 64-card WCST (WCST-64; Heaton et al., 1993) to measure executive 
function, Benton Judgment of Line Orientation Test (Benton et al., 1994) to measure visuospatial 
ability, and the BACS subtests Symbol Coding, Category Instances (categories: animals, fruits, 
vegetables), Digit Sequencing, List Learning, Tower of London, and Token Motor Task (Keefe et 
al., 2004; Keefe et al., 2008) to assess attention/processing speed, verbal working memory, 
verbal learning and memory, executive function, and psychomotor speed, respectively. Data 
including education, duration of illness, and medications were also collected. 
MRI Acquisition. Not applicable. 
Genotyping. DNA from a proportion of participants was obtained from whole blood and 
genotyped on the Illumina HumanOmniZhongHua-8 BeadChip. 
Ethics/Consent. All participants consented to participate in research procedures prior to data 
collection. Consent procedures adhered to the guidelines specified by the National Healthcare 
Group Domain Specific Review Board’s (domain A, NHG DSRB) requirements for human subject 
research. 
Acknowledgements. Data acquisition was supported by the National Research Foundation 
Singapore under the National Medical Research Council Translational and Clinical Research 
Flagship Programme (grant no. NMRC/TCR/003/2008) for The Singapore Translational and 
Clinical Research in Psychosis, as well as research grants from the National Medical Research 
Council under the Centre Grant Programme (Institute of Mental Health, Singapore) 
(NMRC/CG/004/2013), the National Healthcare Group, Singapore (SIG/05004; SIG/05028), and 
the Singapore Bioimaging Consortium (RP C-009/2006). 
KCL-MFS — King’s College London - Maudsley Family Study 
(Psychosis Endophenotypes International Consortium et al., 2014; Toulopoulou et al., 2004; 
Toulopoulou et al., 2003) 
Recruitment. Patients and their relatives were drawn from a larger sample of the Maudsley 
Family Study (Frangou et al., 1997a,b; Griffiths et al., 1998). The relative group comprised mainly 
first-degree relatives and some second degree-relatives. The latter were second degree to the 
proband but they themselves had a first-degree relative with schizophrenia who either did not 
want to participate in this aspect of the Maudsley Family Study or was deceased. All offspring 
were adults. Families were recruited by referrals of psychiatric clinics and various other 
organizations across the United Kingdom. All patients, the vast majority of whom were 
outpatients, met DSM-III-R criteria for schizophrenia or schizoaffective disorder and were on 
antipsychotic medication at the time of the assessment. Among the non-psychotic relatives were 
seven individuals who had had a single episode of major depression, and the following had a 
lifetime diagnosis: 10 recurrent depressive disorder, three schizotypal personality disorder, and 
one of each of bulimia nervosa, alcohol dependency and social phobia. All relatives were well at 
the time of the neuropsychological assessment. Control participants were recruited from a set of 
controls obtained for previous studies conducted at the Institute of Psychiatry, King’s College, 
London, from members of staff at the Institute of Psychiatry and the Bethlem and Maudsley 
Hospitals and via advertisements in the local newspapers. Some participants form part of the 
Psychiatric Genomics Consortium Schizophrenia Working Group dataset (PGC Schizophrenia 
Working Group, 2014). 
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Inclusion/Exclusion Criteria. All participants spoke English as their primary language. The 
normal control sample consisted of healthy participants with no personal or family history, up to 
second degree, of psychotic illness. The following exclusion criteria were used for all participants: 
head trauma resulting in loss of consciousness, drug or alcohol abuse during the 12 months 
before testing, organic brain disease, English as non-primary language and IQ<70. An additional 
exclusion criterion for relatives only was presence of psychosis that did not meet DSM-III-R criteria 
for schizophrenia or schizoaffective disorder. 
Clinical/Neuropsychological Assessment. All patients and relatives were interviewed using the 
Schedule for Affective Disorders and Schizophrenia–Lifetime Version (Spitzer and Endicott, 
1978). The data collected was later supplemented with information from case-notes and from 
other relatives to assign a lifetime DSM-III-R psychiatric diagnosis. Structured assessments of 
schizotypal personality disorder were completed using the paranoid/schizoid and schizotypal 
personality subscale of the Family Interview for Genetic Studies (Nurnberger et al., 1994) derived 
from a reliable informant. Psychotic symptoms were assessed using PANSS (Kay et al., 1987) 
and SANS/SAPS (Andreasen, 1983, 1984). Overall functioning was assessed using GAF 
(American Psychiatric Association, 1994). Current IQ was estimated using 8 subtests of the 
Wechsler Adult Intelligence Scale–Revised (WAIS-R; Wechsler, 1981): Vocabulary, 
Comprehension, Information, Similarities, Block Design, Object Assembly, Picture Completion, 
and Picture Arrangement. Additionally, Vocabulary was used to estimate premorbid IQ. 
Processing speed was assessed using WAIS-R Digit Symbol and a computerized version of the 
Trail Making Test—Part A and B (Army Individual Test Battery, 1944; Reitan, 1958). 
Attention/vigilance was assessed using the CANTAB Rapid Visual Information Processing 
subtest. Verbal working memory was tested using the WAIS-R subtests Digit Span and Arithmetic. 
Spatial working memory was tested using the CANTAB Spatial Working Memory subtest 
(Cambridge Cognition, 2003a). Verbal and visual memory were assessed by the Wechsler 
Memory Scale–Revised (WMS-R) Logical Memory and Visual Reproduction subtests (Wechsler, 
1987), respectively. Verbal and visual learning were measured using the WMS-R Paired 
Associate Learning and Visual Reproduction subtest, respectively.  
MRI Acquisition. Not applicable. 
Genotyping. DNA from a proportion of participants was obtained from whole blood or saliva 
and genotyped on the Affymetrix 6.0 array. 
Ethics/Consent. The study was approved by the UK Multicenter Research Ethics Committee. 
All participants gave written informed consent before participating.
Acknowledgements. Support was provided by the European Community’s Sixth Framework 
Programme through a Marie Curie Training Network (MRTN-CT-2006-035987) called the 
European Twin Study Network on Schizophrenia (EUTwinsS), NARSAD (through a Young 
Investigator Award to Dr. Toulopoulou), Wellcome Trust Research Training Fellowship (grant 
064971 to Dr. Picchioni), Economic and Social Research Council/Medical Research Council and 
the Psychiatry Research Trust (PTA-037-27-0002); Deutsche Forschungsgemeinschaft (grant Et 
31/2-1 to Dr. Ettinger), and Wellcome Trust Training Fellowship (ref 059007 to Dr. McDonald). 
The investigators acknowledge support from the Department of Health via the National Institute 
for Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health award to 
South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry at 
King’s College London. Principal funding for genotyping was provided by the Wellcome Trust, as 
part of the Wellcome Trust Case Control Consortium 2 project (Grant Nos. 085475/B/08/Z and 
085475/Z/08/Z). Dr. Bramon was supported by a MRC New Investigator Award, a MRC 
Centenary Award, the National Institute of Health Research UK (post-doctoral fellowship), the 
Psychiatry Research Trust, the Schizophrenia Research Fund, a Brain and Behavior Research 
Foundation (NARSAD) Young Investigator Award, a Wellcome Trust Research Training 
Fellowship, and the NIHR Biomedical Research Centre for Mental Health at the South London 
and Maudsley NHS Foundation Trust and Institute of Psychiatry Kings College London. 
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Conflicts of interest. Dr. Robin Murray has received honoraria for lectures from Janssen, 
AstraZeneca, Lilly, Novartis and Bristol-Myers Squibb. Dr. Picchioni has received travel awards 
from Pfizer, Janssen-Cilag, and Eli Lily and an educational grant from Janssen-Cilag. 
KCL-MTS — King’s College London - Maudsley Twin Study 
(Owens et al., 2012; Owens et al., 2011a; Owens et al., 2011b; Psychosis Endophenotypes 
International Consortium et al., 2014; Toulopoulou et al., 2007) 
Recruitment. Probands with schizophrenia were recruited nationally throughout the United 
Kingdom from National Health Service treatment centers through referrals by their treating 
psychiatrist. In the United Kingdom, the National Health Service is a comprehensive national 
treatment service funded centrally and free at the point of delivery for all aspects of health care. 
By virtue of its financial and organizational structure, it is hugely inclusive and as a consequence 
cares for most patients with schizophrenia, making it a very representative system from which to 
recruit. Control twins were recruited from a volunteer twin register held at the Institute of 
Psychiatry, London, England. Zygosity was determined by assessment of 12 highly polymorphic 
microsatellite markers and a standardized twin likeness questionnaire. Medication status was 
recorded at the time of the assessment, and age at first contact with psychiatric services was 
ascertained to serve as a proxy index of age at illness onset. In concordant pairs, both members 
fulfilled criteria for DSM-IV schizophrenia or schizoaffective disorder. In discordant pairs, one 
member was diagnosed with DSM-IV schizophrenia, whereas the co-twin was free of any 
psychotic illness. In control pairs, both members were free of personal or family history of 
psychosis or schizophrenia spectrum disorder. Some participants form part of the Psychiatric 
Genomics Consortium Schizophrenia Working Group dataset (PGC Schizophrenia Working 
Group, 2014). 
Inclusion/Exclusion Criteria. Exclusion criteria applied to all groups were: <18 years of age, a 
history of a neurological disorder or systemic illness with known neurological complications, a 
history of significant head injury associated with loss of consciousness for more than 1 minute, 
and current harmful substance use or dependence (defined as within the last 12 months). No 
participant included in the study had a psychotic illness directly attributable to the harmful use of 
illicit substances. 
Clinical/Neuropsychological Assessment. The DSM-IV diagnoses were made using the 
Schedule for Affective Disorders and Schizophrenia (SADS)–Lifetime Version (Spitzer and 
Endicott, 1978), supplemented by information from medical notes or by using the Structured 
Clinical Interview for DSM-IV (First et al., 1995a, b). Psychotic symptoms in the probands in the 
month before testing were assessed using PANSS (Kay et al., 1987) and/or SANS/SAPS 
(Andreasen, 1983, 1984), and overall functioning using GAF (American Psychiatric Association, 
1994). The full UK version of the WAIS-III (WAIS-III-UK; Wechsler, 2005) was administered to all 
participants to assess current IQ, consisting of the following subtests: Vocabulary, 
Comprehension, Information, Similarities, Letter-Number Sequencing, Digit Span, Arithmetic, 
Digit Symbol, Block Design, Object Assembly, Picture Completion, and Picture Arrangement. 
Additionally, Vocabulary was used to estimate premorbid IQ. Furthermore, processing speed was 
assessed using a computerized version of the Trail Making Test—Part A and B (Army Individual 
Test Battery, 1944; Reitan, 1958), Semantic Verbal Fluency (categories: animals, fruits, body 
parts) (Benton and Hamsher, 1989) and COWAT Phonemic Verbal Fluency (letters: F, A, S) 
(Reitan, 1985). Attention/vigilance was assessed using the CANTAB Rapid Visual Information 
Processing subtest (Cambridge Cognition, 2003a). Verbal working memory was tested using the 
WAIS-R subtests Letter-Number Sequencing, Digit Span and Arithmetic. Spatial working memory 
was tested using the WMS-R Visual Memory Span subtest (Wechsler, 1987) and the CANTAB 
Spatial Working Memory subtest (Cambridge Cognition, 2003a). Verbal and visual memory were 
assessed by the WMS-R Logical Memory and Visual Reproduction subtests (Wechsler, 1987), 
respectively. Verbal and visual learning were measured using the WMS-R Paired Associate 
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Learning subtest and Visual Reproduction/Visual Paired Associates subtests, respectively 
(Wechsler, 1987). Executive processing was assessed by the CANTAB Intra-Extra Dimensional 
Set Shifting subtest (Cambridge Cognition, 2003a).  
MRI Acquisition. T1-weighted structural scans (TE = 5.0 ms; TI = 450 ms; TR = 35 ms; Flip 
angle = 30°; FOV = 20 cm; Spatial resolution = 0.78 x 0.78 x 1.5 mm; matrix = 256 x 256 x 128 
mm; Slice acquisition direction = coronal) and Diffusion Tensor Imaging (TE = 102 ms; TR = 
15000 ms; Flip angle = n/a; FOV = 24 cm; Spatial resolution = 2.5 x 2.5 x 2.5 mm; matrix = 96 x 
96 mm; Slice acquisition direction = axial, AC-PC; number of diffusion-encoding gradient 
directions = 64; number of b0 volumes = 7; b-value = 1300 s/mm2) were acquired on a 1.5 Tesla 
GE Signa Advantage scanner using a circularly polarized (CP) head coil.
Genotyping. DNA from a proportion of participants was obtained from whole blood or saliva 
and genotyped on the Affymetrix 6.0 array. 
Ethics/Consent. The study was approved by the UK Multicenter Research Ethics Committee. 
All participants gave written informed consent before participating. 
Acknowledgements. Support was provided by the European Community’s Sixth Framework 
Programme through a Marie Curie Training Network (MRTN-CT-2006-035987) called the 
European Twin Study Network on Schizophrenia (EUTwinsS), NARSAD (through a Young 
Investigator Award to Dr. Toulopoulou), Wellcome Trust Research Training Fellowship (grant 
064971 to Dr. Picchioni), Economic and Social Research Council/Medical Research Council and 
the Psychiatry Research Trust (PTA-037-27-0002). The investigators acknowledge support from 
the Department of Health via the National Institute for Health Research (NIHR) Specialist 
Biomedical Research Centre for Mental Health award to South London and Maudsley NHS 
Foundation Trust (SLaM) and the Institute of Psychiatry at King’s College London. Principal 
funding for genotyping was provided by the Wellcome Trust, as part of the Wellcome Trust Case 
Control Consortium 2 project (Grant Nos. 085475/B/08/Z and 085475/Z/08/Z). Dr. Bramon was 
supported by a MRC New Investigator Award, a MRC Centenary Award, the National Institute of 
Health Research UK (post-doctoral fellowship), the Psychiatry Research Trust, the Schizophrenia 
Research Fund, a Brain and Behavior Research Foundation (NARSAD) Young 
Investigator Award, a Wellcome Trust Research Training Fellowship, and the NIHR Biomedical 
Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust 
and Institute of Psychiatry Kings College London. 
Conflicts of interest. Dr. Robin Murray has received honoraria for lectures from Janssen, 
AstraZeneca, Lilly, Novartis and Bristol-Myers Squibb. Dr. Picchioni has received travel awards 
from Pfizer, Janssen-Cilag, and Eli Lily and an educational grant from Janssen-Cilag. 
L&R — Language and Risk in Schizophrenia 
(Francis et al., 2012) 
Recruitment. Individuals at familial high risk for schizophrenia (FHR) (age range of 19–32 
years) with at least one first degree family member suffering from schizophrenia or schizoaffective 
disorder and one second or third degree relative with history of a psychosis, suicide, or psychiatric 
hospitalization were included in this study. Participants were recruited during 2009–2011 from 
throughout Massachusetts and other New England neighboring regions through brochures and 
advertisements and by networking through the National Alliance on Mental Illness. Controls with 
no family history of a psychosis in 1st, 2nd or 3rd degree relatives (age range of 20–32 years) 
were also recruited from the community via advertisements. 
Inclusion/Exclusion Criteria. Participants with a DSM-IV diagnosis of any history of lifetime 
psychotic disorder were excluded. Additional exclusion factors were: English not the participant's 
native language, non-right-handedness, neurological illness, and IQ below 80. 
Clinical/Neuropsychological Assessment. All participants were administered the Diagnostic 
Interview for Genetic Studies (DIGS; Nurnberger et al., 1994). A family pedigree was drawn with 
information obtained from the participant. DSM-IV diagnoses (Axis I for major psychiatric illness 
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and Axis II for personality disorders) were made on all participants by a research psychiatrist 
using all available information collected during the interview. Schizotypal symptoms were 
measured using the Modified Structured Interview for Schizotypy (SIS; Kendler et al., 1989) from 
the DIGS. Data were acquired on 9 factors from the SIS (magical thinking, ideas of reference, 
illusions, suspiciousness, psychotic-like symptoms, restricted emotion, social isolation/ 
introversion, schizotypal social anxiety, and anger to slights). Participants were administered a 
large neurocognitive test battery including tests estimating premorbid IQ, i.e. the Reading subtest 
from the WRAT-4 (Wilkinson and Robertson, 2006a), and current IQ, i.e. the Vocabulary and 
Block Design subtest of the WASI (Wechsler, 1999). BACS Symbol Coding (Keefe et al., 2008), 
Trail Making Test—Part A (Reitan, 1958), and Semantic Verbal Fluency (MCCB Category 
Fluency; category: animals) (Benton and Hamsher, 1978; Kern et al., 2008; Nuechterlein et al., 
2008) were used for processing speed; the CPT-IP (Cornblatt et al., 1988) was used to measure 
attention/vigilance; the WMS-III Spatial Span subtest (Wechsler, 1997b) and University of 
Maryland Letter-Number Span (Gold et al., 1997) were used for assessing working memory. The 
‘vigilance’, ‘working memory’ and ‘working memory plus interference’ measures from the 
Seidman Auditory CPT (Seidman et al., 1998; Seidman et al., 2006). The HVLT-R (Brandt and 
Benedict, 1997) and the WMS-III Logical Memory subtest (Wechsler, 1997b) assessed verbal 
learning and memory. The BVMT-R (Benedict, 1997) assessed visual learning. Executive function 
was measured using NAB Mazes (Stern and White, 2003) and the computerized WCST (Heaton, 
2003; Heaton et al., 1993; Nestor et al., 1993). The D-KEFS Proverbs subtest (Delis et al., 2001; 
Delis et al., 2004) was administered to assess verbal ability, and Grooved Pegboard (Lafayette 
Instrument Company -- Trites, 1989) and Finger Tapping (Ruff and Parker, 1993) were 
administered to assess motor control. Additionally, participants were administered verbal 
neuropsychological tests to test many aspects of linguistic functioning potentially associated with 
familial high-risk for schizophrenia, including: Abstract Reasoning (Delis et al., 2001), Woodcock-
Johnson Passage Comprehension Test (Woodcock et al., 2001); Phonological Awareness 
derived from auditory stimuli: Elision and Blending Words subtests from the Comprehensive Test 
of Phonological Processing (Wagner et al., 1999); Phonological Awareness derived from visual 
stimuli including real words (WRAT-4 Reading subtest; Test of Word Reading Efficiency [TOWRE] 
Sight Word Efficiency; Woodcock–Johnson Letter Word Identification) and non-words (TOWRE 
Phonemic Decoding Efficiency; Woodcock-Johnson Word Attack) (Torgesen et al., 1999; 
Wilkinson and Robertson, 2006b; Woodcock et al., 2001).  
MRI Acquisition. T1-weighted structural scans (TE = 3.48 ms; TI = 900 ms; TR = 15 ms; Flip 
angle = 9°; FOV = 25.6 cm; Spatial resolution = 1.0 x 1.0 x 1.0 mm; matrix = 256 x 256 mm; Slice 
acquisition direction = sagittal) and Diffusion Tensor Imaging (TE = 84 ms; TR = 8060 ms; Flip 
angle = 55°; FOV = 25.6 cm; Spatial resolution = 2.0 x 2.0 x 2.0 mm; matrix = 128 x 128 mm; 
Slice acquisition direction = axial; number of diffusion-encoding gradient directions = 60; number 
of b0 volumes = 10; b-value = 700 s/mm2) on a 3 Tesla Siemens Trio Tim scanner using a 32-
channel head coil. 
Genotyping. DNA was obtained from whole blood and genotyped on the Illumina Infinium 
PsychArray. Genotyping was funded by the National Institute of Mental Health (NIMH) of the 
National Institutes of Health (NIH) grant number R01MH092380 to T.L.P. supporting the GENUS 
Consortium. 
Ethics/Consent. The study was approved by the Human Subjects Investigation Committee at 
Harvard Medical School, Beth Israel Deaconess Medical Center, Massachusetts Institute of 
Technology, Brigham and Women's Hospital, and Veterans Administration Boston Healthcare 
System, Brockton, Massachusetts. All participants provided written informed consent and were 
paid for their participation. 
Acknowledgements. Data acquisition was funded by NIMH grant R21MH083205 (LE DeLisi), 
R01MH064023 (MS Keshavan), and the Commonwealth Research Center of the Massachusetts 
Department of Mental Health grant SCDMH82101008006 (LJ Seidman). 
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MCIC — Mind Clinical Imaging Consortium 
(Gollub et al., 2013) 
Recruitment. Patients with schizophrenia and demographic, age and sex- matched healthy 
control participants were recruited for this study between July 2004 and July 2006 across four 
research sites—University of New Mexico, University of Minnesota, Massachusetts General 
Hospital, and University of Iowa. The final cohort for whom cognitive and/or MRI data are available 
includes 156 patients and 122 controls. However, the University of Iowa subsample (38 patients, 
25 controls) is not included in the GENUS dataset, resulting in 118 patients and 97 controls 
included in the GENUS dataset. Participants form part of the Enhancing Neuro Imaging Genetics 
Through Meta Analysis (ENIGMA) Schizophrenia Working Group dataset (van Erp et al., 2016). 
Inclusion/Exclusion Criteria. Participants were excluded for reasons such as excessive motion 
during image acquisition, claustrophobia or discomfort during MRI scanning, or a determination 
of ineligibility based on screening exams and tests. All participants were between the ages of 18 
and 60 and spoke English as their native language. To be included in the schizophrenia cohort, 
patients had to meet DSM-IV diagnostic criteria for schizophrenia, schizoaffective disorder or 
schizophreniform disorder. Concerted effort was made to recruit patients early in the course of 
their illness and especially those who were antipsychotic drug naïve. The healthy control 
participants with no current or past history of psychiatric illness including substance abuse or 
dependence were matched within site to the patient cohort for age, sex, and parental education. 
Control participants who had not been diagnosed with any psychiatric disorders, but had been 
medicated with antidepressants, anti-anxiety medication or medication for sleep disturbance were 
included in the study, provided that the duration of their medication did not exceed 2 months of 
lifetime use and no medication was used within the 6 months preceding the baseline MRI scan. 
Control participants who met criteria for current or past history of substance abuse or dependence 
were excluded from the study. Patients were not excluded from the study unless criteria were met 
for current (i.e., within the past month) abuse or dependence except for 6 patients who were found 
to meet criteria for current abuse after the study data was collected. Both patients and controls 
were excluded if they had 1) an IQ less than 70 based on a standardized IQ test, 2) history of a 
head injury resulting in prolonged loss of consciousness, neurosurgical procedure, neurological 
disease, history of skull fracture, severe or disabling medical conditions, or 3) a contraindication 
for MRI scanning such as pregnancy, metal in body or head including implanted pacemaker, 
medication pump, vagal stimulator, deep brain stimulator, implanted TENS unit, or ventriculo-
peritoneal shunt. Clinical teams at each site recruited the patients. Primary treating clinicians, not 
necessarily involved with the study, identified potential patients who met inclusion/ exclusion 
criteria and were competent to give informed consent. Healthy control participants were recruited 
from the community at each site through posters, brochures, newspapers, website 
advertisements, and institutional subject recruitment resources. 
Clinical/Neuropsychological Assessment. Core demographic information collected includes 
age, handedness, height, weight, ethnicity, race, educational achievement, parental education, 
and socioeconomic status. A Structured Clinical Interview for DSM-IV Disorders, SCID-P for 
patients and SCID-NP for controls (First et al., 1995a, b), or the Comprehensive Assessment of 
Symptoms and History (CASH; Andreasen et al., 1992) were used to diagnose primary and co-
morbid psychiatric disorders in controls and patients. Additionally, patients were interviewed with 
the SANS/SAPS (Andreasen, 1983, 1984) and the CDSS (Addington et al., 1992) to record 
symptoms and their current severity. Premorbid IQ and current IQ were measured using the 
Reading subtest of the WRAT-3 (Wilkinson, 1993), and the Block Design, Vocabulary, and 
Similarities subtests of the WAIS-III (Wechsler, 1997a), respectively. Trail Making Test—Part A 
and B (Reitan, 1958) measured processing speed. D-KEFS (Delis et al., 2001) assessed 
Semantic Verbal Fluency (categories: animals, fruits) and Phonemic Verbal Fluency (letters: F, 
A, S). The WAIS-III Letter-Number Sequencing subtest measured working memory. Verbal 
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memory and learning were assessed using the Wechsler Memory Scale—Third Edition (WMS-
III) Logical Memory subtest (Wechsler, 1997b) and the HVLT-R (Brandt, 1991). The Benton Visual 
Retention Test (BVRT; Sivan, 1992) and the Face Recognition subtest of the WMS-III (Wechsler, 
1997b) both measured visual memory. A computerized version of the Tower of London test (TOL; 
Shallice, 1982) was employed to measure planning and problem solving. The Grooved Pegboard 
Test (Ruff and Parker, 1993), and the California Computerized Assessment Package (CalCap; 
Miller, 1990), a computerized reaction time test, tested fine motor dexterity and speed. The Annett 
Scale of Hand Preference (Annett, 1970) provided a numeric measure of handedness. 
MRI Acquisition. T1-weighted structural scans at Massachusetts General Hospital, Martinos 
Center (TE = 4.76 ms; TI = 300 ms; TR = 12.0 ms; Flip angle = 20°; FOV = 16 cm; Spatial 
resolution = 0.7 x 0.7 x 1.5 mm; matrix = 256 x 256 x 128 mm; Slice acquisition direction = axial, 
oblique) and Diffusion Tensor Imaging (TE = 80 ms; TR = 8900 ms; Flip angle = 90°; FOV = 16 
cm; Spatial resolution = 2.0 x 2.0 x 2.0 mm; matrix = 128 x 128 mm; Slice acquisition direction = 
axial; number of diffusion-encoding gradient directions = 60; number of b0 volumes = 10; b-value 
= 700 s/mm2) were acquired on a 1.5 Tesla Siemens Sonata scanner using an 8-channel head 
coil. T1-weighted structural scans at the University of Minnesota (TE = 3.81 ms; TI = 1100 ms; 
TR = 2530 ms; Flip angle = 7°; FOV = 16 cm; Spatial resolution = 0.625 x 0.625 x 1.5 mm; matrix 
= 256 x 256 x 128 mm; Slice acquisition direction = coronal) and Diffusion Tensor Imaging (TE = 
98 ms; TR = 11500 ms; Flip angle = 90°; FOV = 16 cm; Spatial resolution = 2.0 x 2.0 x 2.0 mm; 
matrix = 128 x 128 mm; Slice acquisition direction = axial; number of diffusion-encoding gradient 
directions = 12; number of b0 volumes = 1; b-value = 1000 s/mm2) were acquired on a 3.0 Tesla 
Siemens Trio Tim scanner using an 8-channel head coil. T1-weighted structural scans at the 
University of New Mexico (TE = 4.76 ms; TI = 300 ms; TR = 12.0 ms; Flip angle = 20°; FOV = 16 
cm; Spatial resolution = 0.625 x 0.625 x 1.5 mm; matrix = 256 x 256 x 128 mm; Slice acquisition 
direction = coronal) and Diffusion Tensor Imaging (TE = 92 ms; TR = 10000 ms; Flip angle = 90°; 
FOV = 16 cm; Spatial resolution = 2.0 x 2.0 x 2.0 mm; matrix = 128 x 128 mm; Slice acquisition 
direction = axial; number of diffusion-encoding gradient directions = 12; number of b0 volumes = 
1; b-value = 1000 s/mm2) were acquired on a 1.5 Tesla Siemens Sonata scanner using an 8-
channel head coil. 
Phenotype data are available from the Collaborative Informatics and Neuroimaging Suite 
(https://coins.mrn.org). 
Genotyping. DNA was obtained from whole blood and genotyped on the Illumina 
HumanOmni1-Quad BeadChip. 
Ethics/Consent. All participants provided informed consent to participate in the study. The 
study was approved by the human research committees at each site. In addition to informed 
consent, all patients successfully completed a questionnaire verifying that they understood the 
study procedures. 
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MGH — Massachusetts General Hospital 
(Ho et al., 2016; Holt et al., 2012; Linnman et al., 2013; Roffman et al., 2013; Roffman et al., 2011; 
Roffman et al., 2007; Roffman et al., 2008a; Roffman et al., 2008b) 
Recruitment. Outpatients with schizophrenia were recruited from an urban community mental 
health center in Boston. Demographically matched healthy participants were recruited from the 
community by poster and website advertisements. 
Inclusion/Exclusion Criteria. Participants were excluded if they had a history of substance 
abuse or dependence within the previous 6 months, a history of significant head injury, or 
neurologic illness. Healthy participants were screened to exclude a personal history of Axis I 
mental illness (First et al., 2002a) or a family history of schizophrenia-spectrum disorder. For all 
participants, exclusion criteria included severe medical illness, significant head trauma, 
neurologic illness, substance abuse during the past six months and contraindications for MRI 
scanning (e.g., implanted metal objects, claustrophobia, renal insufficiency). Patients had been 
maintained on stable doses of second generation antipsychotics for at least six weeks, with the 
exception of one patient taking prolixin, and three patients who were not taking any medications. 
Clinical/Neuropsychological Assessment. Patient diagnoses were confirmed using the 
Structured Clinical Interview for DSM-IV-TR (First et al., 2002b). The healthy controls were without 
psychiatric disorders as determined by the Structured Clinical Interview for DSM-IV Axis I 
Disorders (First et al., 1995b). Participants were also rated with the PANSS (Kay et al., 1987), 
Hamilton Depression Rating Scale (HDRS; Hamilton, 1960) and Simpson–Angus Scale (Simpson 
and Angus, 1970), a measure of extrapyramidal symptoms. Tests were administered by one of 
four trained and certified raters. Premorbid IQ was estimated using the North American Adult 
Reading Test (NAART; Blair and Spreen, 1989). The WAIS—III (Wechsler, 1997a) was 
conducted to measure current IQ (all subtests [=13], except Symbol Search). Patients participated 
in a neurocognitive battery that included the CVLT (Delis et al., 1987), Semantic Verbal Fluency 
(category: animals) (Benton and Hamsher, 1989) and COWAT Phonemic Verbal Fluency (letters: 
F, A, S) (Reitan, 1985), WCST (Heaton et al., 1993), and Finger Tapping (Ruff and Parker, 1993).  
MRI Acquisition. Subsample1: T1-weighted structural scans (TE = 1.54 ms, 3.36 ms; TI = 
1100 ms; TR = 2200; Flip angle = 7°; FOV = 23 cm; Spatial resolution = 1.2 x 1.2 x 1.2 mm; matrix 
= 192 x 192 mm; Slice acquisition direction = sagittal) and Diffusion Tensor Imaging (TE = 85.0 
ms; TR = 5980 ms; Flip angle = 90°; FOV = 22 cm; Spatial resolution = 1.375 x 1.375 x 3.0 mm; 
matrix = 160 x 160 mm; Slice acquisition direction = axial; number of diffusion-encoding gradient 
directions = 6; number of b0 volumes = 1; b-value = 1000 s/mm2) were acquired on a 3 Tesla 
Siemens Trio Tim scanner. Subsample 2: T1-weighted structural scans (TE = 3.39 ms; TI = 1100 
ms; TR = 2530 ms; Flip angle = 7°; FOV = 25.6 cm; Spatial resolution = 1.0 x 1.0 x 1.3 mm; matrix 
= 256 x 256 mm; Slice acquisition direction = sagittal) were acquired on a 3 Tesla Siemens Trio 
Tim scanner using a 12-channel head coil. 
Genotyping. DNA was obtained from whole blood or saliva and genotyped on the Illumina 
Infinium PsychArray. Genotyping was funded by the National Institute of Mental Health (NIMH) of 
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the National Institutes of Health (NIH) grant number R01MH092380 to T.L.P. supporting the 
GENUS Consortium. 
Ethics/Consent. Study procedures were approved by the institutional review boards of 
Partners HealthCare and the Massachusetts Department of Mental Health. All participants 
provided written informed consent. 
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NEFS — New England Family Study 
(Buka et al., 2013; Goldstein et al., 2010; Goldstein et al., 2014; Seidman et al., 2013; Seidman 
et al., 2002) 
Case and Control Recruitment. Participants were selected from the Boston and Providence 
cohorts of the Collaborative Perinatal Project (CPP), currently known as the New England Family 
Studies (NEFS). The CPP was initiated over 50 years ago to investigate prospectively the prenatal 
and familial antecedents of pediatric, neurological and psychological disorders of childhood 
(Niswander and Gordon, 1972). Approximately 17,000 pregnancies were followed in New 
England. Many types of assessments, including psychological examinations, were conducted on 
offspring up to 7 years of age, when the study officially ended in 1973. Ascertainment and 
assessment of the adult psychotic patients in NEFS were identified through a systemic follow-up 
of the entire NEFS cohort of the CPP. NEFS parents and offspring with a history of psychiatric 
hospitalization and/or possible psychotic and bipolar illness were identified from the following 
sources: (1) record linkages with public hospitals, mental health clinics, and the Massachusetts 
and Rhode Island Departments of Mental Health; (2) several follow-up and case-control studies 
nested within the larger NEFS cohort, involving direct interviews with approximately 20% of the 
cohort; and (3) reports from participants in these interview studies of a family member with a 
history of psychotic or bipolar symptoms or diagnosis. Controls were selected from families 
participating in the control arm of a NEFS high-risk study in which the control population was a 
random stratified sample of parents selected from the entire NEFS cohort, with no known history 
of psychosis or other major Axis I disorders. Thus, the NEFS sample of cases and controls is a 
representative community sample of subjects. 
Inclusion/Exclusion Criteria. Adult offspring with major non-organic psychoses (including 
schizophrenia, schizoaffective disorder, delusional disorder, brief psychosis, psychosis NOS, 
bipolar disorder with psychotic features, and major depressive disorder with psychosis) within 
NEFS cohorts were identified approximately 30 years later through a two-stage diagnostic 
assessment procedure between 1996 and 2007. The investigators were blind to prior 
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assessments of these subjects during this follow-up. In the first stage, individuals with possible 
psychotic illness were identified through record linkages and from personal interviews. In the 
second stage, those who consented to participate in follow-up efforts were interviewed using the 
SCID (First et al., 1995b). Based on interview data and medical record review, trained PhD- and 
MD-level diagnosticians then completed best-estimate consensus diagnoses according to DSM-
IV criteria for lifetime prevalence of psychotic and other psychiatric disorders. Exclusion criteria 
for all adult participants were a history of neurological disease, traumatic brain injury, medical 
illness or alcohol-related disease with documented cognitive sequelae, major sensory 
impairments (e.g. deafness), IQ<65 in adulthood or inability to understand the procedures, <6 
years of formal education and severe substance abuse within the past 6 months. All psychoses 
cases were living in the community when assessed. Controls had to be free of any known lifetime 
history of psychosis or other major Axis I disorders. Furthermore, parents and grandparents, in 
addition to the parents’ siblings, had to be free of any known lifetime history of psychosis, bipolar, 
schizotypal, recurrent MDD, suicide attempts or psychiatric hospitalizations. Siblings of the 
controls also had to be free of any lifetime history of psychosis or BD. 
Family High Risk Sample Ascertainment: The study goal was to ascertain approximately 200 
psychotic NEFS Generation-1 parents, half with schizophrenia and half with affective psychoses 
and a comparable group of normal control parents. Generation-1 parents were contacted between 
1994 and 2002. Parents with a history of psychiatric treatment were identified by the following 
sources: (1) prior record review; (2) subsequent record linkages with private and public psychiatric 
treatment facilities in Rhode Island and Massachusetts; (3) information provided by mothers 
during the original study (e.g., psychiatric hospitalization at study enrollment; psychiatric treatment 
at the 7 year assessment; or history of treatment with antipsychotic medication); or (4) family 
member reports from recent follow-up studies with the NCPP cohort.  Through these efforts, from 
a total pool of 26,928 G1 parents, we identified 859 persons with indications of potential 
psychosis. This represents a rate of approximately 3.2%-4.2% of the pool of parents we were able 
to review, which is consistent with current estimates of the lifetime prevalence of psychotic 
disorders. Of these parents, 755 were eligible for follow-up. Parents were considered eligible if at 
least one Generation-2 offspring was assessed after 4 months of age.
 Control parents were selected to be comparable to parents with psychotic disorders based 
on the number of offspring enrolled in the CPP, patient status (public or private), parent’s age, 
ethnicity (Caucasian or other), study site, and on the offspring’s age, sex, and history of chronic 
hypoxia (given that we wanted to test for the interaction of genetic vulnerability and this obstetric 
condition).  Eligible controls included all members of the CPP who were not identified as potential 
psychotic parents and whose records did not indicate a history of psychiatric treatment. Healthy 
control parents did not have spouses, parents, siblings, or any second-degree relatives with 
psychoses, recurrent MDD, suicide, or psychiatric hospitalizations. 
Generation-1 Follow-Up and Psychiatric Assessment: Subjects were located through a variety 
of methods, including thorough searches of credit bureaus, address directories, death certificates, 
motor vehicle reports, and by home visits. The located subjects were invited to participate in a 
two-part interview. The first interview screened for potential psychoses and the second was a full 
diagnostic interview using the SCID (First et al., 1995b) and assessing Axis I diagnoses of any 
form of psychotic, major affective, and bipolar disorders; and substance abuse or dependence 
(alcohol and drug). The clinical interview was conducted by systematically trained M.A.-level 
clinical interviewers. Medical records were obtained with subject consent.  Family history of 
psychiatric disorders was evaluated using the Family Interview for Genetic Studies (Maxwell, 
1996). Expert diagnosticians (including J.G., L.S.) reviewed all of the information collected from 
both interviews and medical records, if available, to determine final best estimate diagnoses. If 
there was any evidence of mental illness in the spouse, we interviewed the spouse or searched 
for medical records if the spouse had passed away. Spouses’ names were subjected to the 
linkage procedures used for the mothers. 
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   Of the 755 eligible Generation-1 parents, 212 with confirmed DSM-IV psychotic disorders 
were identified, with 153 (72%) mothers and 59 (27%) fathers. The sample of 212 parents with 
psychosis and 132 non-psychotic parents had a total of 467 pregnancies: 167 offspring among 
affective parents, 114 offspring among SPS parents, and 186 offspring among non-psychotic 
parents.  Of note, among the 344 final Generation-1 parents, there are six ‘two parent families’ in 
which both parents were diagnosed with some form of psychosis, resulting in a sample size of 
338 unduplicated families. Of the 467 pregnancies, 22 (4.7%) resulted in an offspring who was 
stillborn, did not live past early childhood, was lost to follow-up before age 7, or was 
adopted/placed in foster care, and thus ineligible for this adult follow-up study.  Of the 445 eligible 
Generation-2’s, 428 (96.2%) were located of whom 344 (80.4%) were interviewed, for an overall 
interview rate of 77.3%. In addition to the 344 Generation-2’s with diagnostic information from 
interviews, there were an additional six Generation-2’s with a diagnostic summary from medical 
records from treatment facilities for a total of 350 Generation-2’s with diagnostic information. This 
reflects a completed diagnostic rate of 78.7%. 
Clinical/Neuropsychological Assessment. Trained and skilled M.A.-level interviewers and 
neuropsychological testers conducted all clinical and cognitive assessments. The SANS/SAPS 
(Andreasen, 1983, 1984)) were used to measure symptom severity. Participants were 
administered a large neurocognitive test battery including tests estimating premorbid IQ (the 
Reading subtest from the WRAT-3 (Wilkinson, 1993), and current IQ (the Vocabulary, Information, 
Comprehension, Block Design, Picture Arrangement, Digit Span and Digit Symbol subtests of the 
WAIS-R (Wechsler, 1974). The WAIS-R Digit Symbol Coding subtest (Wechsler, 1974) and 
COWAT Phonemic Verbal Fluency test (letters F, A, S) (Reitan, 1985) were used for measuring 
processing speed. The ‘vigilance’, ‘working memory’ and ‘working memory plus interference’ 
measures from the Seidman Auditory CPT (Seidman et al., 1998; Seidman et al., 2006) were 
used to measure attention/vigilance and verbal working memory, in addition to the WAIS-R Digit 
Span subtest for working memory assessment (Wechsler, 1974). The CVLT or CVLT-II (Delis et 
al., 1987, 2000) and the WMS-R or WMS-III Logical Memory subtest (Wechsler, 1987, 1997b) 
assessed verbal learning and memory. The WMS-III Faces subtest (Wechsler, 1997b) and the 
Rey-Osterrieth Complex Figure Test (Rey, 1964) assessed visual learning and memory. 
Executive function was measured using the WCST (Heaton et al., 1993) or the Stroop test 
(Stroop, 1935). Finally, the Rapid Automatized Naming test (Denckla and Rudel, 1974) was used 
to measure language ability. 
MRI Acquisition. T1-weighted structural scans (TE = 3.31 ms; TI = 1000 ms; TR = 2730 ms; 
Flip angle = 7°; FOV = 25.6 cm; Spatial resolution = 1.0 x 1.0 x 1.33 mm; matrix = 256 x 256 mm; 
Slice acquisition direction = sagittal) and Diffusion Tensor Imaging (TE = 77-79 ms; TR = 7200 
ms; Flip angle = 90°; FOV = 25.6 cm; Spatial resolution = 2.0 x 2.0 x 2.0 mm; matrix = 128 x 128 
mm; Slice acquisition direction = axial; number of diffusion-encoding gradient directions = 60; 
number of b0 volumes = 10; b-value = 700 s/mm2) were acquired on a 1.5 Tesla Siemens Avanto 
scanner using a 4-channel head coil. For a second subsample, T1-weighted structural scans (TE 
= 3.39 ms; TI = 1000 ms; TR = 2730 ms; Flip angle = 7°; FOV = 25.6 cm; Spatial resolution = 1.0 
x 1.0 x 1.33 mm; matrix = 256 x 256 mm; Slice acquisition direction = sagittal) and Diffusion 
Tensor Imaging (TE = 67 ms; TR = 9000 ms; Flip angle = 90°; FOV = 25.6 cm; Spatial resolution 
= 2.0 x 2.0 x 2.0 mm; matrix = 128 x 128 mm; Slice acquisition direction = axial; number of 
diffusion-encoding gradient directions = 6; number of b0 volumes = 1; b-value = 600 s/mm2) were 
acquired on a 1.5 Tesla Siemens Sonata scanner using a CP coil. A portion of T1-weighted 
structural scans were acquired also on a 1.5 Tesla Siemens Sonata scanner (TE = 4.3 ms; TI = 
8 ms; TR = 11.8 ms; Flip angle = 8°; FOV = 25.6 cm; Spatial resolution = 1.0 x 1.0 x 1.5 mm; 
matrix = 256 x 256 mm; Slice acquisition direction = sagittal, CP head coil) or on a 1.5T GE 
Genesis Signa scanner (TE = 1.6 ms; TI = 300 ms; TR = 6.7 ms; Flip angle = 25°; FOV = 24 cm; 
Spatial resolution = 0.94 x 0.94 x 1.5 mm; matrix = 256 x 256 mm; Slice acquisition direction = 
sagittal, CP head coil). Given that NEFS is a long-term follow up study, in more recent years, T1-
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weighted scans were acquired on a 3 Tesla Siemens Trio Tim scanner, using a 12-channel head 
coil (TE = 3.39 ms; TI = 1000 ms; TR = 2530 ms; Flip angle = 7°; FOV = 25.6 cm; Spatial resolution 
= 1.0 x 1.0 x 1.33 mm; matrix = 256 x 256 mm; Slice acquisition direction = sagittal) and Diffusion 
Tensor Imaging (TE = 83-84 ms, TR = 9400-9440 ms; Flip angle = 90°; FOV = 25.6 cm; Spatial 
resolution = 2.0 x 2.0 x 2.0 mm; matrix = 128 x 128 mm; Slice acquisition direction = axial; number 
of diffusion-encoding gradient directions = 60; number of b0 volumes = 10; b-value = 700 s/mm2). 
Genotyping. DNA was obtained from whole blood or buffy coat and genotyped on the Illumina 
Infinium PsychArray. Genotyping was funded by the National Institute of Mental Health (NIMH) of 
the National Institutes of Health (NIH) grant number R01MH092380 to T.L.P. supporting the 
GENUS Consortium. 
Ethics/Consent. Human subject research approval was granted by Institutional Review 
Boards at Harvard University, Partners Healthcare, Brown University and local psychiatric 
facilities. Written consent was obtained from all participants interviewed. Participants were 
compensated for their participation.  
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PAGES — Phenomics and Genomics Sample 
(Walters et al., 2010; Walters et al., 2013) 
Recruitment. Clinically stable patients with a DSM-IV diagnosis of schizophrenia were 
ascertained from mental health services in the Munich area. Healthy control participants randomly 
selected from population registers from the Munich area were contacted by mail and invited to 
participate. The address, sex, and age of potential control participants were supplied by the 
municipal registration office, which enabled equal numbers of males and females and people of 
different ages (in decades) to be contacted. In patients, 68% were of German descent (all 4 
grandparents born in Germany), and 32% were German white. All healthy control participants 
were of German descent (all 4 grandparents German). All patients and healthy control participants 
were unrelated. Some patients (62%) and healthy control participants (23%) form part of the 
SGENE-plus study (Stefansson et al., 2009). Some participants form part of the Psychiatric 
Genomics Consortium Schizophrenia Working Group dataset (PGC Schizophrenia Working 
Group, 2014). Controls form part of the Cognitive Genomics Consortium wave 1 (COGENT1) 
dataset (Lencz et al., 2014).  
Inclusion/Exclusion Criteria. The inclusion criteria for patients were a diagnosis of 
schizophrenia (6-month symptom duration) and 18 to 80 years of age. Exclusion criteria were a 
history of head injury or neurological disease. Healthy control participants 18 to 65 years of age 
underwent an extensive screening process (Walters et al., 2010) to exclude those with 
neurological or psychotic disorders, those who had first-degree relatives with psychotic disorders, 
and those with lifetime exposure to psychiatric medication. In the case of healthy controls older 
than 60 years, the Mini-Mental State Examination (Folstein et al., 1983) was employed to exclude 
individuals with possible cognitive impairment. A neurologic examination was also conducted to 
exclude individuals with current central nervous system impairment.  
Clinical/Neuropsychological Assessment. Detailed medical and psychiatric histories were 
collected, including data from a clinical interview using the SCID (First et al., 1995b) to evaluate 
lifetime Axis I and II diagnoses. The interviews were rated by four psychiatrists or one 
psychologist, and all measurements were independently rated by a senior researcher. 
Participants were also rated for symptoms using the PANSS (Kay et al., 1987). In addition, the 
Family History Assessment Module (Rice et al., 1995) was conducted to exclude psychotic 
disorders in first-degree relatives. Current IQ was measured by the full German WAIS-R (Tewes, 
1991), consisting of 11 subtests: Vocabulary, Comprehension, Information, Digit Span, 
Arithmetic, Similarities, Block Design, Picture Completion, Picture Arrangement, Object 
Assembly, and Digit Symbol Coding. Additionally, Vocabulary was used to estimate premorbid 
IQ. All control participants completed the full WAIS-R assessment. All patients and 25% of control 
participants completed an extensive neuropsychological battery consisting of the WAIS-R and the 
following: Trail Making Test—Part A (Reitan, 1958), Semantic Verbal Fluency (categories: 
animals, food) (Benton and Hamsher, 1978), and Phonemic Verbal Fluency (letters: S and P) 
(Reitan, 1985) to assess attention/processing speed; Continuous Performance Test 3–7 Version 
(Nuechterlein and Asarnow, 2004) to assess attention/vigilance; WMS-R Spatial Span subtest 
(Härting et al., 2000; Wechsler, 1987) and a spatial n-back task (Callicott et al., 1998) to assess 
spatial working memory; Verbal Learning and Memory Test (Helmstaedter et al., 2001) or 
Verbaler Lerntest (Sturm and Willmes, 1999), and WMS-R Verbal Paired Associates subtest 
(Härting et al., 2000; Wechsler, 1987) to assess verbal learning and memory; WMS-R Logical 
Memory subtest (Härting et al., 2000; Wechsler, 1987) to assess episodic memory; WMS-R 
Figural Memory, Visual Reproduction, and Visual Paired Associates subtests (Härting et al., 2000; 
Wechsler, 1987) to assess visual learning and memory; and Trail Making Test-Part B (Reitan, 
1958) and WCST (Heaton, 2003; Heaton et al., 1993) to assess executive function. 
MRI Acquisition. Not applicable. 
Genotyping. DNA from a proportion of participants was obtained from whole blood and 
genotyped on the Illumina OmniExpress array or Illumina HumanHap300 array.  
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Ethics/Consent All participants provided written informed consent in accordance with the 
relevant ethics approvals.
Acknowledgements. Parts of the PAGES study were supported by the German Federal 
Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent 
(Integrated Understanding of Causes and Mechanisms in Mental Disorders), under the auspices 
of the e:Med Programme (grant 01ZX1314). 
PHRS — Pittsburgh High Risk Study 
(Bhojraj et al., 2011; Bhojraj et al., 2009) 
Recruitment. The study was conducted at the Western Psychiatric Institute and Clinic, 
Pittsburgh. First- or second-degree relatives of individuals diagnosed with schizophrenia and age- 
and gender-matched healthy comparison participants from an ongoing study at the University of 
Pittsburgh participated in this study. Relatives of patients with schizophrenia or schizoaffective 
disorder were recruited by approaching patients in the clinic and through advertisements. Controls 
were recruited through advertisements in the same community. The relatives and controls were 
included in the GENUS FHR and control groups, respectively. 
Inclusion/Exclusion Criteria. Participants with an IQ<80, lifetime evidence of a psychotic 
disorder, exposure to antipsychotic medications or anti-depressant medications, substance use 
disorder within the last month, significant neurological or medical condition were excluded.  
Clinical/Neuropsychological Assessment. Clinical assessments of all participants, and 
parental diagnoses of schizophrenia or schizoaffective disorder, used the SCID (First et al., 
1995b) and were confirmed using consensus meetings led by senior diagnosticians. None of the 
relatives were diagnosed with psychotic or other psychiatric illnesses and none had received 
antipsychotic medications. In addition to the SCID, the Structured Interview for Prodromal 
Syndromes, including the Scale of Prodromal Symptoms, was administered (Miller et al., 2003). 
Current IQ was assessed using the Block Design, Matrix Reasoning, Vocabulary, and Similarities 
subtests from the WASI (Wechsler, 1999). Verbal fluency was assessed using the Multilingual 
Aphasia Examination (Benton and Hamsher, 1978) including a Phonemic Verbal Fluency task 
(number of words generated in 20 seconds (each) that start with the letter C, F, and L) (Reitan, 
1985) and a Semantic Verbal Fluency task (categories: animals, fruits and vegetables) (Benton 
and Hamsher, 1978). The CPT-IP (Cornblatt et al., 1988), AX-CPT, Spatial Working Memory, 
Word List Memory, and Go-No-Go subtests from Cogtest (Sharma and Bilder, 2004; The 
Cognition Group, 2006) were used to assess attention/vigilance, attention, spatial working 
memory, verbal learning and memory, and executive functioning, respectively. The Penn Visual 
Object Learning Test (Glahn et al., 1997), the Computerized Finger Tapping Test (Coleman et 
al., 1997), and the Penn Emotion Recognition Test (Gur et al., 2002) from the Computerized 
Neurocognitive Battery (CNB; (Gur et al., 2010; Moore et al., 2015; Swagerman et al., 2016)) 
were used to assess visual learning, motor control, and social cognition, respectively. Further, the 
WCST (Heaton et al., 1993) was used to assess executive function. 
MRI Acquisition. T1-weighted structural scans (TE = 5.0 ms; TR = 25 ms; Flip angle = 40°; 
FOV = 24 cm; Spatial resolution = 0.94 x 0.94 x 1.5 mm; matrix = 256 x 192 mm; Slice acquisition 
direction = coronal, AC-PC oblique) were acquired on a 1.5 Tesla GE Genesis Signa scanner 
using a circularly polarized head coil. 
Genotyping. DNA was obtained from whole blood and genotyped on the Illumina Infinium 
PsychArray. Genotyping was funded by the National Institute of Mental Health (NIMH) of the 
National Institutes of Health (NIH) grant number R01MH092380 to T.L.P. supporting the GENUS 
Consortium. 
Ethics/Consent. The study was approved by the University of Pittsburgh Institutional Review 
Board. All participants signed informed consent after the study was fully explained to them. For 
participants <18 years of age, the consent was provided by the parent or guardian, and the 
participants provided informed assent. 
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investigators acknowledge the contributions of Dr. Vishwajit L. Nimgaonkar, Dr. Kodavali 
Chowdari, Dr. Debra M. Mostrose, Jean M. Miewald, Ian Mathew, Brandon M. Hager, and Olivia 
Lutz. 
TCD/NUIG — Trinity College Dublin and National University of Ireland, Galway 
(Donohoe et al., 2009; O'Donovan et al., 2008; Walters et al., 2010; Walters et al., 2013) 
Recruitment. Patients with schizophrenia were recruited from across Ireland. Comparison 
participants were recruited by local media advertisements. Some participants (~50%) form part of 
the Psychiatric Genomics Consortium Schizophrenia Working Group wave 2 dataset (PGC 
Schizophrenia Working Group, 2014). Some controls (~150) form part of the Cognitive Genomics 
Consortium wave 2 (COGENT2) dataset (Trampush et al., 2017). Some participants (~20%) form 
part of the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Schizophrenia 
Working Group dataset (van Erp et al., 2016). 
Inclusion/Exclusion Criteria. Exclusion criteria were a history of head injury or neurological 
disease. The inclusion criteria required that participants had no history of substance abuse in the 
preceding 6 months based on self-report, and had no previous head injury with loss of 
consciousness or a history of seizures. Clinically stable patients with a DSM-IV diagnosis of 
schizophrenia were recruited from 5 sites across Ireland. Control participants were included only 
if they were aged 18 to 65 years and satisfied, based on clinical interview, the criteria of having 
no history of major mental health problems, intellectual disability, or a first-degree relative with a 
history of psychosis. 
Clinical/Neuropsychological Assessment. Diagnosis was confirmed by trained psychiatrists 
using the SCID-I (First et al., 1995b). Additional diagnostic details and clinical sample 
characteristics ascertained at the time of interview included symptom severity as measured with 
SANS/SAPS (Andreasen, 1983, 1984) or PANSS (Kay et al., 1987), overall functioning using GAF 
(American Psychiatric Association, 1994), and medication dosage. Premorbid IQ was measured 
using the Wechsler Test of Adult Reading (Wechsler, 2001). Current IQ was measured using 
selected subtests (Vocabulary, Similarities, Block Design, and Matrix Reasoning) from the UK 
version of the WAIS-III (Wechsler, 2005). Speed of processing was assessed using the Trail 
Making Test—Part A and B (Reitan, 1958). Phonemic Verbal Fluency was assessed using the 
COWAT (Reitan, 1985) (number of words generated in 60 seconds that start on letter F, A and 
S). Attention/vigilance was measured using the 1-9 Continuous Performance Test (Gordon and 
Mettleman, 1987), or in a small subset using the three-letter condition of the CPT-IP (Cornblatt et 
al., 1988). Verbal working memory was measured using the Letter-Number Sequencing subtest 
from the Wechsler Memory Scale, Third Edition (WMS-III; Wechsler, 1997b) and spatial working 
memory using the Spatial Working Memory test from the CANTAB (Cambridge Cognition, 2003b) 
and a spatial n-back task (Callicott et al., 1998). Verbal learning and memory was assessed using 
the CVLT-II Short Form (Delis et al., 2000). Episodic memory was measured using the Logical 
Memory immediate and delayed tests from the WMS-III (Wechsler, 1997b). Visual learning and 
memory was assessed using the WMS-III Faces subtest (Wechsler, 1997b) and the CANTAB 
Paired Associates Learning subtest. Executive Functioning was assessed using the CANTAB 
Intra-Extra Dimensional Set Shifting subtest (Cambridge Cognition, 2003b) and the Sustained 
Attention to Response Task (Robertson et al., 1997). Finally, social cognition was measured using 
the Hinting Task (Versmissen et al., 2008) and Reading the Mind in the Eyes Test (Baron-Cohen 
et al., 2001). 
MRI Acquisition. For the subsample recruited from Trinity College Dublin, T1-weighted 
structural scans (TE = 3.8 ms; TR = 8.4 ms; Flip angle = 8°; FOV = 23 cm; Spatial resolution = 
0.9 x 0.9 x 0.9 mm; matrix = 256 x 256 mm; Slice acquisition direction = axial) and Diffusion 
Tensor Imaging (TE = 52 ms; TR = 12445 ms; Flip angle = 90°; FOV = 22.4 cm; Spatial resolution 
= 1.75 x 1.75 x 2.2 mm; matrix = 128 x 128 mm; Slice acquisition direction = axial; number of 
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diffusion-encoding gradient directions = 15; number of b0 volumes = 1; b-value = 800 s/mm2) 
were acquired on a 3 Tesla Philips Intera Achieva scanner at the Trinity College Institute for 
Neuroscience using a SENSE 8-channel head coil. For the subsample recruited from National 
University of Ireland Galway, T1-weighted structural scans (TE = 4.38 ms; TI = 600 ms; TR = 
1140 ms; Flip angle = 15°; FOV = 23 cm; Spatial resolution = 0.45 x 0.45 x 0.9 mm; matrix = 512 
x 512 mm; Slice acquisition direction = axial) were acquired on a 1.5 Tesla Siemens Magnetom 
Symphony scanner using a 4-channel head coil.  
Genotyping. DNA from a proportion of participants was obtained from whole blood and 
genotyped on the Affymetrix 6.0 or Illumina HumanCore Exome arrays. 
Ethics/Consent. Assessments of all patient and control participants were conducted in 
accordance with the relevant ethics committee approval from each participating site. All patients 
and controls were of Irish ancestry (4 grandparents born in Ireland), and all provided written 
informed consent. 
Acknowledgements. Recruitment and genotyping were supported by the Wellcome Trust and 
Science Foundation Ireland (SFI08/IN.1/B1916, A Corvin). Dr Donohoe is also supported by the 
European Research Council (ERC-2015-STG-677467). The investigators thank Prof. John 
Waddington, Prof. Ted Dinan, Prof. Eadbhard O’Callaghan, Prof. Kieran Murphy, and Dr. F. 
Anthony O’Neil for their role in the recruitment of the patient sample. 
UMCU-SZ1 — University Medical Centre Utrecht, Schizophrenia study 1 
(Hulshoff Pol et al., 2001; Terwisscha van Scheltinga et al., 2012; Terwisscha van Scheltinga et 
al., 2013a; Terwisscha van Scheltinga et al., 2013b) 
Recruitment. Patients with schizophrenia or schizoaffective disorder were recruited from 
various outpatient and inpatient clinics; treatment setting was unrelated to age. Comparison 
control participants were matched with the patients for the socioeconomic status of their parents, 
which was expressed as the highest level of education completed by one parent. Participants 
form part of the Psychiatric Genomics Consortium Schizophrenia Working Group dataset (PGC 
Schizophrenia Working Group, 2014) and the Enhancing Neuro Imaging Genetics Through Meta 
Analysis (ENIGMA) Schizophrenia Working Group dataset (van Erp et al., 2016). 
Inclusion/Exclusion Criteria. All participants were between 16 and 70 years of age. 
Participants with a major medical or neurological illness, including past head trauma, 
hypertension, cardiac disease, diabetes mellitus, cerebrovascular disease, epilepsy, migraine, 
endocrine disorders, drug or alcohol dependence, or an IQ below 80 were excluded. Control 
participants had no history of psychiatric illness except for three participants who had a history of 
anxiety disorder, obsessive–compulsive disorder and adjustment disorder, respectively. None of 
the control participants had first-degree family members with psychotic illness. 
Clinical/Neuropsychological Assessment. Clinical diagnosis was determined using the 
Comprehensive Assessment of Symptoms and History (CASH; Andreasen et al., 1992)) and  the 
Schedule for Affective Disorders and Schizophrenia (Endicott and Spitzer, 1978) and was 
assessed by two independent raters. Diagnostic consensus was achieved in the presence of a 
psychiatrist. The PANSS (Kay et al., 1987) and GAF (American Psychiatric Association, 1994) 
were used to measure symptom levels and overall functioning, respectively. Premorbid IQ was 
estimated using the Dutch version of the NART (Schmand et al., 1991). Current IQ was estimated 
with the Dutch version of the WAIS-III (Stinissen et al., 1970; Wechsler, 2000). Four out of 11 
subtests of WAIS-III were used: Block Design, Comprehension, Vocabulary and Picture 
arrangement. Raw scores were multiplied by 11/4 to obtain an estimate of total IQ. Verbal fluency 
was assessed using the Multilingual Aphasia Examination (Benton and Hamsher, 1978) including 
a Phonemic Verbal Fluency task (number of words generated in 60 seconds that start on letter N, 
A and P) and a Semantic Verbal Fluency task (category: animals). Sustained visual attention and 
vigilance were assessed using the Continuous Performance Task-HQ (CPT A-X; Nuechterlein 
and Dawson, 1984)), with outcome parameters of reaction time and accuracy. Verbal learning 
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and memory was assessed with the CVLT (Delis et al., 1987). Episodic memory was assessed 
using the Logical Memory subtests from the Dutch WMS-R (Wechsler, 1987). Visual learning 
memory was assessed using the WMS-R Visual Reproduction subtests. Executive functioning 
was assessed using the Stroop test (Stroop, 1935). 
MRI Acquisition. T1-weighted structural scans (TE = 4.6 ms; TR = 30 ms; Flip angle = 30°; 
FOV = 25.6 cm; Spatial resolution = 1.0 x 1.0 x 1.2 mm; matrix = 256 x 256 mm; Slice acquisition 
direction = coronal) were acquired on a 1.5 Tesla Philips NT Intera scanner using a 6-element 
SENSE receiver head coil. 
Genotyping. DNA from a proportion of participants was obtained from whole blood and 
genotyped on the Illumina HumanHap550 or Illumina Infinium OmniExpressExome-8 arrays. 
Genotype data are available from the NIMH Repository and Genomics Resource 
(http://www.nimhgenetics.org). 
Ethics/Consent. The study was approved by the Medical Ethical Committee of the University 
Medical Center Utrecht. 
Acknowledgements. The study was supported by grants 7F99.(2).37 (H Hulshoff Pol) and 
14F06(2)-34 (SC Bakker) from the HersenStichting Nederland (Dutch Brain Foundation), The 
Hague, the Netherlands, by a Veni grant from Zorg Onderzoek Nederland, Medische 
Wetenschappen to SC Bakker (the Dutch organization for health research and development, 
project number: 91686137), and by Top Institute Pharma (project T5-203). Genome-wide SNP 
genotyping was funded by NIMH grant R01MH078075 (RA Ophoff).  
UMCU-SZ2 — University Medical Centre Utrecht, Schizophrenia study 2 
(Boos et al., 2013; Korver et al., 2012; Rais et al., 2012; Terwisscha van Scheltinga et al., 2013a) 
Recruitment. Data pertain to baseline measures of a longitudinal study (GROUP) in the 
Netherlands and Belgium. In selected representative geographical areas, patients were identified 
through clinicians working in regional psychotic disorder services whose caseloads were 
screened for inclusion criteria. Subsequently, a group of patients presenting consecutively at 
these services as either outpatients or in-patients were recruited for the study. Controls were 
selected through a system of random mailings to addresses in the catchment areas of the 
patients. Participants form part of the Psychiatric Genomics Consortium Schizophrenia Working 
Group dataset (PGC Schizophrenia Working Group, 2014). 
Inclusion/Exclusion Criteria. Inclusion criteria for patients, siblings, and controls were: (1) age 
range of 16–50 years and (2) good command of the Dutch language. Patients had to meet 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-
TR) criteria for a non-affective psychotic disorder (American Psychiatric Association, 2000). 
Exclusion criteria for healthy controls were a history of psychotic disorder or a first-degree family 
member with a history of psychotic disorder. 
Clinical/Neuropsychological Assessment. Diagnosis was assessed with the Comprehensive 
Assessment of Symptoms and History interview (CASH; Andreasen et al., 1992) or the Schedules 
for Clinical Assessment for Neuropsychiatry (SCAN) version 2.1 (Wing et al., 1990). The PANSS 
(Kay et al., 1987) and GAF (American Psychiatric Association, 1994) were used to measure 
symptom levels and overall functioning, respectively. Additionally, the Structured Interview for 
Schizotypy-Revised (SIS-R; Vollema and Ormel, 2000) and the CDSS (Addington et al., 1992) 
were administered. The cognitive assessment took between 90 and 120 min. The following 
subtests of the WAIS-III (Wechsler, 1997a) were assessed: Digit Symbol Coding as a measure 
of processing speed; Arithmetic as a measure of working memory; Information as a measure of 
acquired knowledge; and Block Design as a measure of reasoning and problem solving. Together, 
these 3 subtests were used to estimate Current IQ. Sustained visual attention and vigilance were 
assessed using the Continuous Performance Task-H-Q, a variation of the CPT A-X by 
Nuechterlein and Dawson, 1984), with outcome parameters of reaction time and accuracy. Verbal 
learning was assessed using the Auditory Verbal Learning Test (Brand and Jolles, 1985), with 
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outcome parameters of immediate recall (15-word list, three learning trials) and retention rate 
after 20 min. Set shifting ability was assessed using the Response Shifting Task, a modified 
version of the Competing Programs Task (Bilder et al., 1992; Nolan et al., 2004), with outcome 
parameters of reaction time and accuracy. The Degraded Facial Affect Recognition Task (van 't 
Wout et al., 2004) was used to assess recognition of neutral, happy, fearful and angry emotions. 
The Benton Face Recognition Task (Benton et al., 1983) was used to assess visuospatial 
discrimination of unfamiliar faces. The Hinting Task (Versmissen et al., 2008) was used to assess 
theory of mind. 
MRI Acquisition. T1-weighted structural scans (TE = 4.6 ms; TR = 30 ms; Flip angle = 30°; 
FOV = 25.6 cm/70%; Spatial resolution = 1.0 x 1.0 x 1.2 mm; matrix = 256 x 256 mm; Slice 
acquisition direction = coronal) and Diffusion Tensor Imaging (TE = 88 ms, TR = 9822 ms; Flip 
angle = 90°; FOV = 24 cm; Spatial resolution = 2.0 x 2.0 x 2.0 mm; matrix = 128 x 96 mm; Slice 
acquisition direction = axial; number of diffusion-encoding gradient directions = 32; number of b0 
volumes = 8; b-value = 1000 s/mm2) were acquired on a 1.5 Tesla Philips Achieva scanner using 
a 6-element SENSE receiver head coil. 
Genotyping. DNA from a proportion of participants was obtained from whole blood and 
genotyped on the Affymetrix 6.0, Illumina HumanHap550, or Illumina Infinium 
OmniExpressExome-8 arrays. Genotype data are available from the NIMH Repository and 
Genomics Resource (http://www.nimhgenetics.org). 
Ethics/Consent. The study protocol was approved centrally by the Ethical Review Board of 
the University Medical Center Utrecht and subsequently by local review boards of each 
participating institute. All participants gave written informed consent in accordance with the 
committee’s guidelines.
Acknowledgements. The study was funded through the Geestkracht programme of the Dutch 
Health Research Council (ZON-MW, grant number 10-000-1001), and matching funds from 
participating industry (Lundbeck, AstraZeneca, Eli Lilly, Janssen Cilag), universities and mental 
health care organizations in the Netherlands. Genome-wide SNP genotyping was funded by 
NIMH grant R01MH078075 (RA Ophoff). 
ZHH — Zucker Hillside Hospital 
(Lencz et al., 2014) 
Recruitment. Healthy participants from the New York metropolitan area were recruited through 
advertisements, word of mouth, referrals, and study registries. Participants form part of the 
Cognitive Genomics Consortium wave 1 (COGENT1) dataset (Lencz et al., 2014). 
Inclusion/Exclusion Criteria. Participants had no history of a current or past DSM-IV axis I 
major mood or psychotic disorder as assessed by structured diagnostic interview (First et al., 
1995a). Other exclusion criteria included: intellectual or learning disability; significant medical 
illness that could affect brain structure; or lifetime exposure to psychiatric medication. 
Clinical/Neuropsychological Assessment. Premorbid IQ was estimated using the WRAT-3 
(Wilkinson, 1993). Further cognitive testing was performed using the MATRICS Consensus 
Cognitive Battery (MCCB) (Kern et al., 2008; Nuechterlein et al., 2008). Speed of processing was 
assessed using the BACS Symbol Coding subtest (Keefe et al., 2008), the WAIS-R Digit Symbol 
subtest (Wechsler, 1981), Trail Making Test—Part A and B (Reitan, 1958), Semantic Verbal 
Fluency (MCCB Category Fluency; category: animals) (Kern et al., 2008; Nuechterlein et al., 
2008), and COWAT Phonemic Verbal Fluency (letters F, A, S) (Benton and Hamsher, 1978; 
Reitan, 1985); attention using the CPT-IP (Cornblatt et al., 1988); working memory using the 
WMS-III Spatial Span subtest (Wechsler, 1997b), University of Maryland Letter-Number Span 
(Gold et al., 1997), and the WAIS-R Digit Span subtest (Wechsler, 1981); verbal learning using 
the HVLT-R (Brandt and Benedict, 1997)); visual learning using the BVMT-R (Benedict, 1997); 
reasoning and problem solving using the WCST (Heaton et al., 1993) and NAB Mazes (Stern and 
White, 2003); and social cognition using the MSCEIT (Mayer et al., 2003). 
28
MRI Acquisition. Not applicable. 
Genotyping. DNA obtained from whole blood was genotyped on the Illumina OmniExpress 
array. 
Ethics/Consent. This study was approved by the Institutional Review Board of the North Shore 
– Long Island Jewish Health System. Written informed consent was obtained from all participants. 
Acknowledgements. The study was supported by the Donald and Barbara Zucker Foundation, 
internal funding from the North Shore-Long Island Jewish Health System, and grants from the 
Stanley Foundation (EJ Bromet), the National Alliance for Research on Schizophrenia and 
Depression (AK Malhotra), and the NIMH (K23MH001760, R01MH079800, and P50MH080173 
to AK Malhotra, R01MH0084098 and RC2MH089964 to T Lencz, R01MH044801 to EJ 
Bromet, R01MH060374 to RM Bilder, and Center Grants P30MH074543 to JM Kane and 
M01RR018535 to KJ Tracey).  
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Supplementary Table 1. Description of the GENUS Consortium Sample Collection (subset with ge
Acronym Sample Site
CAMH
Centre for Addiction and Mental 
Health
Toronto, Canada
CATIE
Clinical Antipsychotic Trials of 
Intervention Effectiveness
Multi-site, USA
CIDAR/VA
Longwood Study of Psychosis 
consortium / VA Healthcare System
Boston, USA
COGS-UK
Cognition and Genetics in 
Schizophrenia & Bipolar Disorder
Cardiff, UK
GAP
Genetics and Psychosis First-
Episode Study
London, UK
IMH-SIGNRP
Institute of Mental Health - 
Singapore Imaging Genetics and 
Neuropsychological Research in 
Psychosis
Singapore
IMH-STCRP
Institute of Mental Health - 
Singapore Translational and Clinical 
Research in Psychosis
Singapore
KCL-MFS
King’s College London - Maudsley 
Family Study
London, UK
KCL-MTS
King’s College London - Maudsley 
Twin Study
London, UK
L&R
Language and Risk in 
Schizophrenia
Boston, USA
MCIC Mind Clinical Imaging Consortium Multi-site, USA
MGH Massachusetts General Hospital Boston, USA
NEFS New England Family Study Boston, USA
PAGES Phenomics and Genomics Sample Munich, Germany
PHRS Pittsburgh High Risk Study Pittsburgh, USA
TCD/NUIG
Trinity College Dublin/ National 
University of Ireland, Galway
Multi-site, Ireland
UMCU-SZ1
University Medical Center Utrecht  - 
Schizophrenia Study 1
Utrecht, 
Netherlands
UMCU-SZ2
University Medical Center Utrecht - 
Schizophrenia Study 2
Utrecht, 
Netherlands
ZHH Zucker Hillside Hospital New York, USA
Totals
Data in this table are based on genotyped participants only.
All samples that acquired T1 MRI scans also acquired DTI scans except the PHRS and UMCU-SZ1 
samples.Population ancestry determined from genetic data (where available) or self report.
Eur = European-derived ancestry; FHR = familial high-risk.
notype data).
GWAS Array
Neuropsychological data
Patients Controls FHR Male Eur 
(N) (N) (N) (%) (%)
Illumina OmniExpress 90 107 0 54.8 76.1
Affymetrix 500K; Perlegen’s custom 
164K chip
741 0 0 73.6 54.7
Illumina OmniExpress 74 106 5 68.1 60.0
Illumina Infinium 
OmniExpressExome-8
529 0 0 60.7 97.3
Illumina HumanCore-24 Exome 
BeadChip
136 127 0 59.3 46.8
Illumina Human OmniZhongHua-8; 
Illumina Human1M-Duo; Affymetrix 
6.0
104 3 0 51.4 0
Illumina HumanOmniZhongHua-8 
BeadChip
419 956 0 53.0 0
Affymetrix 6.0 10 12 19 56.1 95.1
Affymetrix 6.0 18 65 5 35.2 100
Illumina Infinium PsychArray 0 30 41 36.6 74.7
Illumina HumanOmni1-Quad 
BeadChip
80 66 0 69.9 75.3
Illumina Infinium PsychArray 423 0 0 72.1 68.8
Illumina Infinium PsychArray 75 125 24 47.3 86.2
Illumina OmniExpress; Illumina 
HumanHap300
210 1,341 0 50.0 99.6
Illumina Infinium PsychArray 0 18 43 47.5 41.0
Affymetrix 6.0; Illumina HumanCore 
Exome
826 165 0 63.3 99.9
Illumina HumanHap550; Illumina 
Infinium OmniExpressExome-8
50 96 0 68.5 98.6
Illumina HumanHap550; Affymetrix 
6.0; Illumina Infinium 
OmniExpressExome-8
189 115 168 58.7 97.5
Illumina OmniExpress 0 219 0 49.3 100
3,974 3,551 305 56.6 72.2
Data in this table are based on genotyped participants only.
All samples that acquired T1 MRI scans also acquired DTI scans except the PHRS and UMCU-SZ1 
Population ancestry determined from genetic data (where available) or self report.
Eur = European-derived ancestry; FHR = familial high-risk.
T1-weighted structural MRI data
Patients Controls FHR Male Eur 
(N) (N) (N) (%) (%)
89 115 0 55.4 76.5
--- --- --- --- ---
66 100 5 67.3 60.2
--- --- --- --- ---
67 35 0 60.8 37.3
159 3 0 59.9 0
--- --- --- --- ---
--- --- --- --- ---
7 20 3 50.0 100
0 31 44 36.0 76.0
82 68 0 69.3 74.7
44 110 0 62.3 72.7
66 126 14 46.6 84.0
--- --- --- --- ---
0 11 33 45.5 45.5
134 189 0 54.5 99.7
74 101 0 69.7 98.3
154 103 151 58.8 97.6
--- --- --- --- ---
942 1,012 250 56.6 71.0
Supplementary Table 2. Clinical and demographic characteristics of the GENUS Consortium Sam
Patients
N Mean ± SD (Range)
Age (years) 4,101 39.8±12.1 (13-82)
Education Level (years) 3,740 12.2±2.5 (1-22)
Premorbid IQ 2,644 96.2±15.7 (44-145)
Current IQ 1,478 93.9±18.4 (47-155)
Illness Duration (years) 3,296 15.0±11.5 (<1-58)
Age at Onset (years) 3,278 24.5±8.3 (1-62)
Global Assessment of Functioning 1,396 60.4±15.7 (20-100)
PANSS Positive symptoms 2,507 16.7±7.3 (7-47)
PANSS Negative Symptoms 2,504 17.1±7.2 (7-42)
PANSS General Symptoms 2,510 32.7±12.0 (0-93)
SAPS Positive Symptoms 1,149 9.1±13.3 (0-121)
SANS Negative Symptoms 887 24.4±20.3 (0-103)
Antipsychotic dose – current CPZEQ 2,727
379.9±414.8 (0-
5,000)
Antipsychotic dose – lifetime average CPZEQ 1,355
334.6±360.8 (0-
3,125)
N %
Sex (male / female; % male)
2,721 / 
1,381
66.3
Antipsychotic medication
Atypical 1,691 48.2
Typical 350 10.0
Both Typical and Atypical 517 14.7
Naïve / None 375 10.7
Unknown Class 236 6.7
No information 338 9.6
Diagnosis
Schizophrenia 3,321 81.0
Schizoaffective Disorder 340 8.3
Schizophreniform Disorder 67 1.6
Bipolar Psychosis 207 5.1
Other Psychosis 150 3.7
Psychosis Unknown Type 17 0.4
Ethnicity
European 2,835 69.1
East Asian 624 15.2
African 454 11.1
American (Predominantly Latino) 138 3.4
South Asian 42 1
Mixed 11 0.3
Handedness (right / other; % right-handed) 1,508 / 151 90.1
Data in this table are based on genotyped participants only. CPZEQ = chlorpromazine 100 mg equivalent; df = degree
ple Collection (subset with genotype data).
Controls Familial High Risk
Statistic df
N Mean ± SD (Range) N Mean ± SD (Range)
3,851 40.3±16.1 (8-86) 306 27.2±8.9 (10-64) F = 125.2 2, 8255
3,200 13.1±2.5 (6-26) 305 13.0±3.2 (3-20) F = 101.0 2, 7242
1,060 107.7±10.8 (62-145) 70 104.4±16.8 (45-134) F = 242.2 2, 3771
2,229 113.8±14.8 (71-161) 287 104.4±15.4 (58-152) F = 668.9 2, 3991
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
N % N %
1,935 / 1,916 50.2 133 / 173 43.5 χ2 = 238.5 2
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
--- --- --- --- --- ---
χ
2 = 451.2 10
2,703 70.2 264 86.3 --- ---
982 25.5 1 0.3 --- ---
111 2.9 35 11.4 --- ---
28 0.7 3 1 --- ---
26 0.7 3 1 --- ---
1 0.1 0 0 --- ---
1,816 / 194 90.3 272 / 21 92.8 χ2 = 1.9 2
p<1x10-10
<1x10-10
<1x10-10
<1x10-10
---
---
---
---
---
---
---
---
---
---
<1x10-10
---
---
---
---
---
---
---
---
---
---
---
---
<1x10-10
---
---
---
---
---
---
0.38
Supplementary Table 3. Sample size by neuropsychological test across GENUS Consortium samp
Domain Attention / Processing Speed
Digit Symbol Coding TMT-A Verbal Fluency
BACS 
Symbol 
Coding*
WAIS Digit 
Symbol-
Coding
RBANS 
Symbol 
Coding
TMT-A*
Semantic/
Category 
Fluency - 
Animals*
Semantic/
Category 
Fluency  - 
Any
Phonemic/
Letter 
Fluency
CAMH x x RBANS COWAT
CATIE x x COWAT
CIDAR/VA x x MCCB x
COGS-UK x x MCCB x
GAP III x x x COWAT
IMH-SIGNRP x BACS COWAT
IMH-STCRP x BACS BACS
KCL-MFS R x
KCL-MTS III-UK x x x COWAT
L&R x x MCCB x
MCIC x D-KEFS D-KEFS D-KEFS
MGH III x x COWAT
NEFS R COWAT
PAGES R-DE x x x x
PHRS MAE MAE MAE
TCD/ NUIG x COWAT
UMCU-SZ1 MAE MAE MAE
UMCU-SZ2 III-NL
ZHH x x MCCB x COWAT
N Patients 1,470 1,909 116 1,549 3,139 3,414 2,626
N Controls 1,405 2,156 114 1,116 2,445 2,611 1,647
N FHR 50 346 0 196 247 247 229
N Total 2,925 4,411 230 2,861 5,831 6,272 4,502
*MATRICS test.
References for all neuropsychological tests are provided in the Supplemental Materials.
Abbreviations:128-P, 128-C = 128-card paper, computerized version; 64-P, 64-C = 64-card paper, computerized version; ACPT = Auditory CPT; AVLT = Auditory Verbal Learning Test; BACS = Brief Assessment of 
Cognition in Schizophrenia; BVMT-R= Brief Visuospatial Memory Test-Revised; BVRT = Benton Visual Retention Test; CANTAB = Cambridge Neuropsychological Test Automated Battery; CFT = Complex Figure Test; 
CMS = Children’s Memory Scale; CNB = Computerized Neurocognitive Battery; CPT(-IP) = Continuous Performance Test (Identical Pairs); CVLT(-SF) = California Verbal Learning Test (Short Form); DE = German 
version; D-KEFS = Delis–Kaplan Executive Function System; FHR = Familial High Risk; FigMem = Figural Memory; HVLT = Hopkins Verbal Learning Test; IDED = Intra-Extra Dimensional Set Shifting; JOLO = Judgment 
of Line Orientation; NAB = Neuropsychological Assessment Battery; NL = Dutch version; PAL = Paired Associates Learning; RAN = Rapid Automatized Naming; RBANS = Repeatable Battery for the Assessment of 
Neuropsychological Status; RST = Response Shifting Task; RVIP = Rapid Visual Information Processing; SART = Sustained Attention to Response Task; SDRT = Spatial Delayed Response Task; SOC = Stockings of 
Cambridge; SWM = Spatial Working Memory; TOL = Tower of London; TMT-A, B = Trail Making Test Part A, B; UK = British version; UMD = University of Maryland; VisMemSpan = Visual Memory Span; VisPA = Visual 
Paired Associates; VisRep = Visual Reproduction; VLMT = Verbal Learning and Memory Test; VLT = Verbaler Lern Test; VOLT = Visual Object Learning Test; WASI = Wechsler Abbreviated Scale of Intelligence; WISC = 
Wechsler Intelligence Scale for Children; WMS = Wechsler Memory Scale; WAIS = Wechsler Adult Intelligence Scale; WCST = Wisconsin Card Sorting Test
les (genotyped + ungenotyped).
Attention / Vigilance
Continuous Performance
CPT-IP* ACPT
CANTAB 
RVIP
3-7 CPT A-X CPT 1-9 CPT H-Q CPT X-Y CPT
x
x x
x
x
x
x
x x
x
x
x
x x
x x x
x
x
x
2,337 122 44 201 0 83 246 85
1,410 256 74 411 22 60 198 42
119 83 21 0 66 0 211 0
3,866 461 139 612 88 143 655 127
Abbreviations:128-P, 128-C = 128-card paper, computerized version; 64-P, 64-C = 64-card paper, computerized version; ACPT = Auditory CPT; AVLT = Auditory Verbal Learning Test; BACS = Brief Assessment of 
Cognition in Schizophrenia; BVMT-R= Brief Visuospatial Memory Test-Revised; BVRT = Benton Visual Retention Test; CANTAB = Cambridge Neuropsychological Test Automated Battery; CFT = Complex Figure Test; 
s Memory Scale; CNB = Computerized Neurocognitive Battery; CPT(-IP) = Continuous Performance Test (Identical Pairs); CVLT(-SF) = California Verbal Learning Test (Short Form); DE = German 
Kaplan Executive Function System; FHR = Familial High Risk; FigMem = Figural Memory; HVLT = Hopkins Verbal Learning Test; IDED = Intra-Extra Dimensional Set Shifting; JOLO = Judgment 
of Line Orientation; NAB = Neuropsychological Assessment Battery; NL = Dutch version; PAL = Paired Associates Learning; RAN = Rapid Automatized Naming; RBANS = Repeatable Battery for the Assessment of 
Neuropsychological Status; RST = Response Shifting Task; RVIP = Rapid Visual Information Processing; SART = Sustained Attention to Response Task; SDRT = Spatial Delayed Response Task; SOC = Stockings of 
Cambridge; SWM = Spatial Working Memory; TOL = Tower of London; TMT-A, B = Trail Making Test Part A, B; UK = British version; UMD = University of Maryland; VisMemSpan = Visual Memory Span; VisPA = Visual 
Paired Associates; VisRep = Visual Reproduction; VLMT = Verbal Learning and Memory Test; VLT = Verbaler Lern Test; VOLT = Visual Object Learning Test; WASI = Wechsler Abbreviated Scale of Intelligence; WISC = 
Wechsler Intelligence Scale for Children; WMS = Wechsler Memory Scale; WAIS = Wechsler Adult Intelligence Scale; WCST = Wisconsin Card Sorting Test
Working Memory –  verbal Working Memory – non-verbal
Letter-Number Span Other Spatial Span
UMD 
Letter-
Number 
Span*
WAIS 
Letter-
Number 
Sequencin
g
RBANS 
Digit Span
WAIS/WM
S Digit 
Span
BACS Digit 
Sequencin
g
WAIS/WM
S 
Arithmetic
WMS-III 
Spatial 
Span*
WMS-R-
UK Visual 
Memory 
Span
x x
x
x x
x x
III x
x
x
R R
III-UK III-UK III-UK x
x x
III
III III III
R
R-DE R-DE
III
III-NL
x R x
1,734 1,168 565 115 637 1,001 1,024 73
468 616 1,075 141 1,889 1,752 429 181
49 30 0 0 114 314 50 26
2,251 1,814 1,640 256 2,640 3,067 1,503 280
Abbreviations:128-P, 128-C = 128-card paper, computerized version; 64-P, 64-C = 64-card paper, computerized version; ACPT = Auditory CPT; AVLT = Auditory Verbal Learning Test; BACS = Brief Assessment of 
Cognition in Schizophrenia; BVMT-R= Brief Visuospatial Memory Test-Revised; BVRT = Benton Visual Retention Test; CANTAB = Cambridge Neuropsychological Test Automated Battery; CFT = Complex Figure Test; 
s Memory Scale; CNB = Computerized Neurocognitive Battery; CPT(-IP) = Continuous Performance Test (Identical Pairs); CVLT(-SF) = California Verbal Learning Test (Short Form); DE = German 
Kaplan Executive Function System; FHR = Familial High Risk; FigMem = Figural Memory; HVLT = Hopkins Verbal Learning Test; IDED = Intra-Extra Dimensional Set Shifting; JOLO = Judgment 
of Line Orientation; NAB = Neuropsychological Assessment Battery; NL = Dutch version; PAL = Paired Associates Learning; RAN = Rapid Automatized Naming; RBANS = Repeatable Battery for the Assessment of 
Neuropsychological Status; RST = Response Shifting Task; RVIP = Rapid Visual Information Processing; SART = Sustained Attention to Response Task; SDRT = Spatial Delayed Response Task; SOC = Stockings of 
Cambridge; SWM = Spatial Working Memory; TOL = Tower of London; TMT-A, B = Trail Making Test Part A, B; UK = British version; UMD = University of Maryland; VisMemSpan = Visual Memory Span; VisPA = Visual 
Paired Associates; VisRep = Visual Reproduction; VLMT = Verbal Learning and Memory Test; VLT = Verbaler Lern Test; VOLT = Visual Object Learning Test; WASI = Wechsler Abbreviated Scale of Intelligence; WISC = 
Working Memory – non-verbal Verbal Learning & Memory
Other Word List Learning
SDRT
CANTAB 
SWM
n-back
Cogtest 
SWM
HVLT* CVLT CVLT-SF BACS
x x
R
R
x
x
x
x
x
R
R
x
x / II
x
x
x x x
I-NL
x R
656 792 268 0 1,737 562 100 558
0 448 433 48 426 227 36 1,074
0 21 0 68 50 32 0 0
656 1,261 701 116 2,213 821 136 1,632
Verbal Learning & Memory
Word List Learning Story Recall Other
RBANS AVLT
Cogtest 
WLMT
VLMT
WMS 
Logical 
Memory
CMS 
Logical 
Memory
RBANS 
Stories
WMS 
Verbal 
Paired 
Associate
s
x x
III x
III
R R
R-UK R-UK
III
III
R/ III
x R-DE R-DE
x
III
x
116 213 0 206 1,330 6 116 388
141 142 49 426 863 13 141 705
0 231 71 0 82 0 0 177
257 586 120 632 2,275 19 257 1,270
Visual Learning & Memory
BVMT-R*
RBANS 
Figure 
Recall
WMS 
Figural 
Memory
WMS Visual 
Reproductio
n
WMS 
Faces
BVRT Rey CFT
WMS 
Visual 
Paired 
Associate
s
x
x
x
III
R
R-UK R-UK
x
R III x
III x
R-DE R-DE R-DE
III
R-NL
x
897 115 206 655 712 112 32 279
328 140 427 950 458 95 116 608
48 0 0 228 25 0 31 26
1,273 255 633 1,833 1,195 207 179 913
Reasoning / Problem Solving
Planning
CANTAB 
PAL
CNB VOLT
NAB 
Mazes*
WISC-III 
Mazes
BACS TOL TOL TOL-DE
CANTAB 
SOC
x
x
x
x
x
x
x
x
x
x
x
x
x
608 0 903 715 551 93 202 109
242 50 328 0 1,075 84 427 117
0 56 50 0 0 0 0 0
850 106 1,281 715 1,626 177 629 226
Reasoning / Problem Solving
Set 
Shifting + 
Planning 
Cognitive Flexibility / Set 
Shifting
Response Inhibition
TMT-B
WCST 64-
Card
WCST 128-
Card
CANTAB 
IDED
Stroop RST SART
Cogtest  
Go-No-Go
x x
64-C
64-C
x
64-P
x x
x x
64-C
x
64-C 128-C
128-P x
x 128-C
128-P x
x x x
x
x
x 128-P x
836 1,001 375 522 201 194 513 0
1,408 132 703 285 404 129 182 49
145 57 77 21 0 209 0 70
2,389 1,190 1,155 828 605 532 695 119
Visuo-spatial Ability
WAIS 
Block 
Design
WAIS Matrix 
Reasoning
WAIS 
Object 
Assembly
WAIS 
Picture 
Arrangemen
t
WAIS 
Picture 
Completion
RBANS 
JOLO
Benton 
JOLO
x
WASI
III III
WASI x
R R R R
III-UK III-UK III-UK III-UK
WASI
III
III III III III III
R R
R-DE R-DE R-DE R-DE
III-R-UK III-R-UK
III-R-NL III-R-NL
III-NL
2,260 1,149 311 456 330 116 417
2,744 1,385 1,340 1,607 1,347 141 1,012
522 0 0 33 0 0 0
5,526 2,534 1,651 2,096 1,677 257 1,429
Verbal Ability
RBANS 
Figure Copy
Rey CFT 
Copy
WAIS 
Vocabular
y
WAIS 
Comprehensio
n
WAIS 
Information
WAIS 
Similarities
D-KEFS 
Proverbs
x
WASI x
III
R R R R
III-UK III-UK III-UK III-UK
WASI x
III III
III III III III
x R R R
R-DE R-DE R-DE R-DE
III-R-UK III-R-UK
III-R-NL III-R-NL
III-NL
116 32 1,754 456 1,027 1,140 66
140 116 2,425 1,607 1,645 1,935 128
0 33 285 33 233 253 48
256 181 4,464 2,096 2,905 3,328 242
179
